WO2020082787A1 - 基于数据处理的中药处方药品费用风险控制方法及装置 - Google Patents

基于数据处理的中药处方药品费用风险控制方法及装置 Download PDF

Info

Publication number
WO2020082787A1
WO2020082787A1 PCT/CN2019/094998 CN2019094998W WO2020082787A1 WO 2020082787 A1 WO2020082787 A1 WO 2020082787A1 CN 2019094998 W CN2019094998 W CN 2019094998W WO 2020082787 A1 WO2020082787 A1 WO 2020082787A1
Authority
WO
WIPO (PCT)
Prior art keywords
chinese medicine
monitored
cost
drug
unit
Prior art date
Application number
PCT/CN2019/094998
Other languages
English (en)
French (fr)
Inventor
袁刚
Original Assignee
平安医疗健康管理股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 平安医疗健康管理股份有限公司 filed Critical 平安医疗健康管理股份有限公司
Publication of WO2020082787A1 publication Critical patent/WO2020082787A1/zh

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Definitions

  • the present application relates to the medical technology field, and in particular to a data processing-based method and device for risk control of prescription drug cost risk in traditional Chinese medicine.
  • Various medication monitoring mechanisms are used to monitor medication for various medical units, including but not limited to medical units (or representatives of medical units) such as various hospitals, departments of various hospitals, various clinics, and even various physicians.
  • the evaluation of the medication standard of each medical unit mainly adopts the second-average Chinese medicine prescription standard, that is, the daily average cost of Chinese medicine decoction pieces for each Chinese medicine prescription (referred to as the second-average Chinese medicine prescription cost) is used as the medicine of each medical unit evaluation standard.
  • the evaluation criteria for the above-mentioned average Chinese medicine prescription costs are calculated by dividing the total prescriptions by the number of prescriptions.
  • Existing technology adopts the secondary average Chinese medicine prescription cost as the evaluation standard of the traditional Chinese medicine prescription of each medical unit. As a result, each medical unit is evaluated in order to avoid large prescriptions.
  • the number of prescription days is reduced to reduce the average Chinese traditional medicine prescription cost, or by decomposing the prescription
  • the method divides the large prescription with a large total prescription into multiple small prescriptions with a small total prescription to reduce the average cost of prescriptions of traditional Chinese medicines, thereby avoiding the monitoring of large prescriptions.
  • the medication evaluation method of the prior art makes the loopholes of the medication monitoring of each medical unit larger, the accuracy rate of the medication evaluation of each medical unit is low, and the applicability is weak.
  • the embodiments of the present application provide a data processing-based method and device for controlling the risk of traditional Chinese medicine prescription drug costs.
  • the operation is simple, which can improve the accuracy of monitoring the use of traditional Chinese medicine prescriptions in medical units, and improve the reliability and applicability of medical monitoring of medical units Stronger.
  • an embodiment of the present application provides a data processing-based risk control method for prescription drug cost risk of traditional Chinese medicine.
  • the method includes:
  • the Chinese medicine prescription of the medical unit to be monitored includes at least one Chinese medicine decoction
  • the above-mentioned unilateral daily average drug cost and the above-mentioned unilateral daily average drug cost threshold corresponding to the medical unit to be monitored determine whether the use of traditional Chinese medicine decoction in the medical unit to be monitored exceeds the standard;
  • the risk of exceeding the standard of the medicine cost of the Chinese medicine to the monitored unit shall be controlled based on the above-mentioned unilateral average daily drug cost.
  • an embodiment of the present application provides a data processing-based Chinese medicine prescription drug cost risk control device, which includes:
  • the data acquisition unit is used to acquire the prescription of the traditional Chinese medicine of the medical unit to be monitored, and the above-mentioned prescription of the traditional Chinese medicine includes at least one dose of decoction of traditional Chinese medicine;
  • the medicine information processing unit is used to obtain the medicine medicine information of each piece of Chinese medicine decoction in the Chinese medicine prescription obtained by the data obtaining unit, and determine the unilateral average daily drug cost of the medical unit to be monitored based on the medicine medicine information of the medicine;
  • the medication evaluation unit is used to determine whether the usage of the TCM decoction pieces of the medical unit to be monitored exceeds the standard based on the unilateral average daily drug cost determined by the drug information processing unit and the unilateral average daily drug cost threshold corresponding to the medical unit to be monitored;
  • the medication risk control unit is used to conduct the herbal medicine for the medical unit to be monitored based on the unilateral average daily drug cost determined by the pharmaceutical information processing unit when the medication evaluation unit determines that the medication of the herbal medicine for the medical unit to be monitored exceeds the standard Risk control of excessive costs.
  • an embodiment of the present application provides a terminal device.
  • the terminal device includes a processor and a memory, and the processor and the memory are connected to each other.
  • the memory is used to store a computer program that supports the terminal device to execute the method provided in the first aspect and / or any possible implementation manner of the first aspect
  • the computer program includes program instructions
  • the processor is configured to call the foregoing Program instructions to execute the method provided in the first aspect and / or any possible implementation manner of the first aspect.
  • an embodiment of the present application provides a computer-readable storage medium storing a computer program, the computer program including program instructions, which when executed by a processor causes the processor to execute The method provided in the foregoing first aspect and / or any possible implementation manner of the first aspect.
  • the operation of monitoring the medication use of each medical unit is simple, which can improve the accuracy of the medication monitoring of the medical unit, improve the reliability of the medication monitoring of the medical unit, and increase the effective utilization of medical resources. More applicable.
  • FIG. 1 is a schematic flowchart of a data processing-based risk control method for prescription drug cost based on data processing provided by an embodiment of the present application;
  • FIG. 1 is a schematic flowchart of a data processing-based risk control method for prescription drug cost based on data processing provided by an embodiment of the present application;
  • FIG. 2 is another schematic flowchart of a data processing-based risk control method for prescription drug cost based on data processing provided by an embodiment of the present application;
  • FIG. 3 is a schematic structural diagram of an embodiment of a data processing-based risk control device for prescription drug costs of traditional Chinese medicine provided by an embodiment of the present application;
  • FIG. 4 is a schematic structural diagram of an embodiment of a terminal device provided by an embodiment of the present application.
  • the embodiments of the present application provide a data processing-based risk control method for prescription drug costs of traditional Chinese medicine, which can be based on various hospitals, departments of various hospitals, various clinics, and even various medical units (or representatives of medical units (or teams))
  • the average daily drug cost of a single party (that is, the average daily drug cost of a single Chinese medicine prescription) is used to evaluate whether the medical prescriptions of various medical units (including hospitals, departments, clinics or physicians) exceed the standard (or reasonable), and can be based on medical
  • the unit ’s use of Chinese medicine prescriptions is to publicize the medical unit ’s prescriptions with a unilateral daily average drug cost exceeding the standard, and / or to reject the Chinese medicine decoction drug cost reimbursement corresponding to the unilateral daily average drug cost exceeding the risk of exceeding the standard Control to avoid the waste of medical resources.
  • the assessment dimensions expressed by the representatives of the above-mentioned hospitals, departments of various hospitals, clinics, and even doctors or other medical units or medical units will be described using the evaluation dimension of the medical unit as an
  • the prescriptions of traditional Chinese medicine provided in the embodiments of the present application may include prescriptions of traditional Chinese medicine prescribed by various doctors of various medical units for the conditions of each patient, or prescriptions of traditional Chinese medicine prescribed by various doctors for the conditions of each patient, or prescription papers, etc. , No restrictions here.
  • the prescription will be described as an example below.
  • the prescriptions issued by various doctors in various medical units may include, but are not limited to, the prescription issuance time, prescription number, department number, patient personal information, medicine details of Chinese herbal medicines, and the signature of the doctor, depending on the actual application scenario Ok, no restrictions here.
  • each prescription will contain the details of the Chinese herbal medicines prescribed by the medical unit. , Including but not limited to the name of Chinese herbal medicines, the amount of Chinese herbal medicines, the use of Chinese herbal medicines, and the number of days of Chinese herbal medicines used. Therefore, no matter whether it is a large prescription or a small prescription or other, it is inseparable from the details of medicines in Chinese herbal medicines. Therefore, based on the unilateral average daily drug cost of each medical unit, the use of traditional Chinese medicine prescriptions in each medical unit can be evaluated to monitor the medical use of each medical unit. The operation is simple and can cover the medical unit better and more comprehensively.
  • the unilateral average daily drug cost based on the medical unit can achieve more accurate monitoring of the drug use of each medical unit, which can improve the accuracy of the drug monitoring of each medical unit, and thus can improve the prescription of traditional Chinese medicine based on each medical unit.
  • the medical unit ’s prescriptions for traditional Chinese medicines can be publicized for unilateral daily average drug costs exceeding the standard, and / or the risk control of the Chinese medicine prescriptions for excessive prescription drug costs for traditional Chinese medicine prescriptions such as reimbursement of drug costs corresponding to unilateral daily average drug costs exceeding the reliability can be improved.
  • the controllability of the medication used by the unit prescribing can improve the effective utilization of medical resources and have higher applicability.
  • the traditional Chinese medicine decoction piece is a traditional Chinese medicine that can be directly used in the clinical practice of traditional Chinese medicine after being processed according to the traditional Chinese medicine theory and the traditional Chinese medicine preparation method.
  • Chinese herbal decoctions include some traditional Chinese medicine slices processed in the place of origin, original medicinal decoctions, and cut and fired decoctions.
  • Common varieties of Chinese herbal medicines include but are not limited to: 1, dried ginger; 2, gun ginger; 3, ginger charcoal; 4, rhubarb; 5, wine rhubarb; 6, cooked rhubarb; 7, rhubarb charcoal; 8, gardenia; 9. Jiao Gardenia; 10.
  • the above-mentioned traditional Chinese medicine decoction pieces are only examples, not exhaustive, and can be determined according to actual application scenario requirements, and are not limited herein.
  • the data processing-based traditional medicine prescription drug cost risk control method provided by the embodiments of the present application can be executed by terminal devices associated with drug monitoring units such as the Drug Administration, Health Commission, Health and Health Commission, and medical claim units, such as the above drug monitoring units Clients and / or human-computer interaction devices used to monitor medication use of various medical units are not limited here.
  • drug monitoring units such as the Drug Administration, Health Commission, Health and Health Commission
  • medical claim units such as the above drug monitoring units
  • Clients and / or human-computer interaction devices used to monitor medication use of various medical units are not limited here.
  • the terminal device will be taken as an example for description below.
  • FIG. 1 is a schematic flowchart of a data processing-based risk control method for prescription drug cost based on data processing provided by an embodiment of the present application.
  • the method for controlling the risk of traditional Chinese medicine prescription drug costs based on data processing provided by the embodiments of the present application can be described by the implementation manners provided in the following steps S11 to S14.
  • the above-mentioned medical unit to be monitored may be any medical unit monitored by the medication monitoring unit, which may be specifically determined according to actual application scenarios, and is not limited herein.
  • any medical unit may be monitored by the medication monitoring unit, so the selected monitoring object may be the medical unit to be monitored.
  • the medical unit to be monitored will be described as an example below.
  • the traditional Chinese medicine prescription of the above medical unit may include all the traditional Chinese medicine prescriptions generated by the medical unit to be monitored within a single day of any day, including but not limited to all physicians in all departments of the hospital within a single day All Chinese medicine prescriptions issued, all Chinese medicine prescriptions issued by all doctors in a hospital department within a single day, or all Chinese medicine prescriptions issued by a doctor in a hospital department within a single day happening.
  • the specific conditions indicated in the above traditional Chinese medicine prescription are determined according to the evaluation dimension of the medical unit's medication evaluation in the actual application scenario, and no limitation is made here.
  • the method provided in the embodiments of the present application may calculate the average daily drug cost of a Chinese herbal medicine tablet included in any Chinese medicine prescription (referred to as a single side for convenience of description) based on the above-mentioned various Chinese medicine prescriptions, and may be based on any Chinese medicine prescription
  • the unilateral daily average drug cost evaluates the medical unit's medication. Based on the single-party average daily drug cost of Chinese herbal medicines included in the single party, the medical unit is evaluated for the drug standard, the granularity is finer, and the drug monitoring is more strict and effective. For the convenience of description, the following will take the unilateral average daily drug cost of Chinese herbal medicines included in a single prescription of traditional Chinese medicine as an example for explanation, hereafter referred to as the unilateral average daily drug cost.
  • a prescription can include one or more doses of Chinese herbal medicine, each of which can include one or more varieties (or Kind) Chinese herbal medicine pieces.
  • a prescription can include one or more doses of Chinese medicine decoctions, each of which includes one or more varieties of Chinese medicine decoctions.
  • All kinds of Chinese herbal medicines in one piece of Chinese herbal medicine are mixed and used together.
  • the way of taking all kinds of Chinese medicine slices in one Chinese medicine slice is to put them in a casserole or enamel pan for mixing after mixing, and finally get a bowl of medicine soup.
  • the number of days of use of all Chinese herbal medicines in a single prescription is the cumulative value of the number of days of use of each Chinese herbal medicine in the prescription.
  • it may also be called the total number of days of medicine usage as an example for explanation. For example, if the Chinese herbal medicines included in a single prescription have M doses, and the usage days of each Chinese herbal medicine are one day, then the total number of days of using the Chinese herbal medicines included in the above prescriptions is M (that is, M * 1) days.
  • the terminal device can be docked with the data system of the medical unit to be monitored to obtain the access qualification of the data system of the medical unit to be monitored, and from the medical system to be monitored based on the data system access qualification of the medical unit to be monitored Obtain the Chinese medicine prescription of the medical unit to be monitored in the unit's data system.
  • the terminal device may also screen the medical claim data from the medical claim data based on the medical claim data provided by the medical institution to be monitored to obtain prescription data such as the Chinese medicine prescription of the medical institution.
  • the terminal device can also obtain prescription data such as prescriptions of traditional Chinese medicines of the medical unit to be monitored from the medical records of patients in various medical units based on big data analysis, and so on.
  • the terminal device can obtain the prescription of the traditional Chinese medicine of the medical unit to be monitored based on any data acquisition path other than the above-mentioned data acquisition method, which can be determined according to the actual application scenario, without limitation.
  • any prescription of the Chinese medicine prescription of the medical unit to be monitored here can include the details of the medicine prescribed in the prescription, including but not limited to the name of the medicine, the cost of the medicine, the way of using the medicine (or the way of taking the medicine, etc.) As well as the number of days the drug is used, it can be determined according to the actual application scenario, and is not limited here.
  • the terminal device after the terminal device obtains the traditional Chinese medicine prescription of the medical unit to be monitored (such as a single traditional Chinese medicine prescription, or simply a single party), it can obtain the traditional Chinese medicine decoction drug information of each of the traditional Chinese medicine decoction pieces included in the single traditional Chinese medicine prescription , Including but not limited to the cost of medicine and the number of days the medicine is used. Based on the single Chinese medicine prescription of the medical unit to be monitored, the medicine costs of various Chinese medicine decoction pieces included in each of the Chinese medicine decoction pieces in the single Chinese medicine prescription can be obtained, and the total drug cost of the single Chinese medicine decoy can be determined according to the medicine cost of the various Chinese medicine decoction pieces.
  • the total cost of the above-mentioned single Chinese herbal medicine prescription is the cumulative value of the cost of one or more Chinese herbal medicine pieces in a single Chinese herbal medicine prescription.
  • the cost of each Chinese herbal medicine is the cumulative value of the cost of each Chinese herbal medicine in the Chinese herbal medicine.
  • the cost of any Chinese herbal medicine in a single Chinese herbal medicine is the unit price of the Chinese herbal medicine and the single Chinese medicine in a single dose. The product of the dose.
  • the total medicine cost of the single Chinese medicine prescription may also be the cumulative value of the medicine costs of various Chinese medicine decoction pieces included in the single Chinese medicine prescription, where the drug cost of a single Chinese medicine decoction piece is the unit price of the Chinese medicine decoction piece and the The product of the sum of the doses of Chinese herbal medicines in a single Chinese medicine prescription can be determined according to the actual application scenario.
  • the total cost of the medicine for a single Chinese medicine prescription is not limited here. Based on the accumulated value of the drug costs of each dose of Chinese herbal medicines in one or more doses of Chinese herbal medicines, the total drug cost of all Chinese herbal medicines in the Chinese medicine prescription can be obtained.
  • the total number of days of Chinese medicine prescription can be determined according to the number of days of use of each piece of Chinese medicine pieces in the traditional Chinese medicine pieces, and the single party of the medical unit to be monitored can be determined based on the total cost of the above medicines and the total number of days of the above medicine Average daily drug cost.
  • the total number of days of use of the above-mentioned single Chinese medicine prescription pieces of Chinese medicine pieces is one or more doses of the Chinese medicine pieces of the Chinese medicine pieces of the cumulative number of days of drug use.
  • the average daily drug cost of a single Chinese medicine prescription of the medical unit to be monitored represents the average daily drug cost of all Chinese herbal medicines in the single Chinese medicine prescription of the medical unit to be monitored. It can be calculated based on the following formula (1):
  • the total cost of the above-mentioned Chinese medicine decoction is the cumulative value of the cost of one or more doses of a single Chinese medicine prescription, where the cost of each Chinese medicine decoction is all included in the Chinese medicine decoction The accumulation of the cost of each Chinese herbal medicine in Chinese herbal medicine.
  • the total number of days of use of the above-mentioned Chinese medicine decoction refers to the cumulative value of the number of days of use of each Chinese medicine decoction in one or more doses of Chinese medicine decoction included in the Chinese medicine prescription.
  • the evaluation thresholds of the drug monitoring standards and / or drug evaluation standards of each medical unit may be set in advance, for example, the upper limit of the daily drug cost of a single party is not exceeded ( Or called the unilateral daily average drug cost limit).
  • the daily average drug cost limit corresponding to the medical unit to be monitored can be set based on the historical drug records of the medical unit to be monitored or the drug use policy, etc., and then based on the determined The unilateral daily drug cost of the monitored medical unit is combined with the threshold of the assessment index corresponding to the medical unit to be monitored (ie, the upper limit of the unilateral daily drug cost) to determine whether the medical unit's medication exceeds the standard.
  • the average daily drug cost of the medical unit to be monitored is less than or equal to the upper limit of its corresponding average daily drug cost. If the unilateral average daily drug cost of the medical unit to be monitored is less than or equal to the upper limit of the corresponding unilateral average daily drug cost, it can be determined that the medical unit to be monitored does not exceed the standard. If the average daily drug cost of the medical unit to be monitored is greater than the upper limit of the corresponding average daily drug cost of the corresponding unit, it can be determined that the medication of the medical unit to be monitored is exceeding the standard, that is, the medical cost of the medical unit to be monitored exceeds the standard.
  • the medication of the medical unit to be monitored exceeds the standard, for example, the average daily drug cost of the medical unit to be monitored is greater than the threshold of the average daily drug cost of the medical unit to be monitored, the unilateral daily drug The difference of the average daily drug cost of the part that exceeds the threshold of the average daily drug cost of the party. Based on the above-mentioned unilateral daily average drug cost difference, the above-mentioned unilateral daily average drug cost and / or the above-mentioned unilateral daily average drug cost difference can be publicized.
  • the doctor of the medical unit to be monitored controls the prescribing medication of the Chinese medicine prescription, to avoid the waste of medicine and other medical resources caused by the random use of the medicine by the doctor of the medical unit to be monitored during the prescribing process, and to achieve the risk of exceeding the standard for the cost of the Chinese medicine prescription for the monitoring medical unit control.
  • the medical unit medication monitoring daily report issued by the unit is published to control the prescription of Chinese medicine prescriptions of the medical unit to be monitored and its various doctors, to avoid the medical treatment caused by the continuous daily excess of the traditional Chinese medicine prescription of the medical unit to be monitored. Resources are wasted, and the risk of over-medication of the medical unit to be monitored is controlled.
  • each doctor's prescribing tool can be publicized on the homepage of the prescription tool, which can be determined according to the actual application scenario, and is not limited here.
  • the medicine monitoring operation of the Chinese medicine prescription of each medical unit is simple, which can improve the accuracy of the medicine monitoring of the Chinese medicine prescription of the medical unit, improve the reliability of the medicine monitoring of the medical unit, and thus can improve
  • the reliability of the risk control of over-the-counter drug costs for medication prescriptions improves the controllability of the prescription medication of the Chinese medicine prescription of the medical unit, thereby improving the effective utilization of medical resources and making it more applicable.
  • FIG. 2 is another schematic flowchart of a data processing-based risk control method for prescription drug cost based on data processing provided by an embodiment of the present application.
  • the data processing-based traditional medicine prescription drug cost risk control method provided by the embodiments of the present application can realize the monitoring of the medication situation of the medical unit to be monitored in a single assessment cycle. This method can be implemented by the following steps S21 to S25 Way to explain.
  • the implementation manner of obtaining the traditional Chinese medicine prescription of the medical unit to be monitored may refer to the implementation manner provided in step S11 in the foregoing embodiment, and details are not described herein again.
  • the traditional Chinese medicine prescription of the medical unit may further include all traditional Chinese medicine prescriptions generated by the medical unit to be monitored within a single assessment cycle, where the single assessment period is one day or greater than one day, for example One week, one month, one quarter or one year, etc., no restriction is made here.
  • the single assessment period is one day or greater than one day, for example One week, one month, one quarter or one year, etc., no restriction is made here.
  • all the traditional Chinese medicine prescriptions generated by the above-mentioned medical unit to be monitored in a single assessment cycle can be explained by taking the single assessment cycle prescription as an example.
  • the single assessment cycle prescription of the medical unit may refer to all prescriptions issued in any assessment cycle of the medical unit, including but not limited to all prescriptions issued by all doctors in all departments of the hospital in a single assessment cycle, and a single All the prescriptions issued by all the doctors in a certain department of the hospital during the assessment cycle, or all the prescriptions issued by a certain doctor in a certain department of the hospital in a single assessment cycle.
  • the specific conditions indicated in the above single assessment cycle prescriptions are based on the evaluation dimensions of drug monitoring of medical units in actual application scenarios (for example, drug monitoring for medical units, drug monitoring for a department of the medical unit, or A certain doctor in a certain department conducts medication monitoring, etc.), and it is not restricted here.
  • the following will take all prescriptions issued by all doctors in all departments of the hospital in a single assessment cycle as an example for explanation, hereinafter referred to as a single assessment cycle prescription.
  • any Chinese medicine prescription included in the single assessment cycle prescription of the medical unit to be monitored here can include the medicine details of the Chinese medicine decoction pieces included in the Chinese medicine prescription, including but not limited to the medicine name, medicine cost, medicine use
  • the method and days of drug use can be determined according to the actual application scenario, and there is no limit here.
  • the specific implementation manner of determining the unilateral average daily drug cost of the medical unit to be monitored based on the information of the traditional Chinese medicine pieces of the Chinese herbal medicine pieces included in the traditional Chinese medicine prescription of the medical unit to be monitored can be found in the above embodiment The implementation provided in step S12 will not be repeated here.
  • the unilateral average daily drug cost based on the traditional Chinese medicine prescription of the medical unit to be monitored may also be processed to obtain the unilateral average daily drug cost of the medical unit to be monitored within a specified time period, for example, one day , A week, a month, a quarter or a year, the average daily drug cost, etc.
  • a specified time period for example, one day , A week, a month, a quarter or a year, the average daily drug cost, etc.
  • the following can be used as an assessment cycle for a week, taking a week's average daily drug cost as an example for explanation, referred to as the average daily drug cost for a single prescription cycle prescription.
  • the average daily drug cost per prescription for a single assessment cycle can meet the following formula (2):
  • the total cost of the periodic medicines in the above formula (2) may be the total cost of the medicines of all the traditional Chinese medicine decoctions included in all the traditional Chinese medicine decoctions included in all the prescriptions of the traditional Chinese medicines in a single evaluation period, and the total number of days of the use of the above-mentioned periodic medicines It may be the accumulated value of the number of days of use of each Chinese herbal medicine in all Chinese herbal medicines included in the prescription for a single assessment period.
  • any single-day Chinese medicine prescription on any day in a single assessment cycle may be obtained, and Obtain the Chinese herbal medicine information of each Chinese herbal medicine included in the Chinese medicine prescription on any single day, where the Chinese herbal medicine information includes but is not limited to the medicine cost and the number of days of medicine use.
  • the unilateral average daily drug cost on any day of the medical unit to be monitored may refer to the implementation manner corresponding to the formula (2) in the above embodiment, which will not be repeated here.
  • the total number of days of medicine use in all Chinese medicine prescriptions per day can be determined, which can be based on all The total number of days for the use of medicines for prescriptions of traditional Chinese medicines determines the total number of days for the use of medicines for all pieces of Chinese herbal medicines included in the single assessment cycle prescription of the medical unit to be monitored.
  • the total number of days of use of Chinese herbal medicines on any day within a single assessment period of the medical unit to be monitored is the sum of the days of use of each Chinese herbal medicines included in all Chinese medicine prescriptions on any single day. According to the above-mentioned average daily drug cost and the total number of days of use of the traditional Chinese medicine prescriptions for each day of a single evaluation cycle of the medical unit to be monitored, the average daily drug cost of the medical unit to be monitored within a single evaluation cycle can be determined.
  • the cumulative average value of the unilateral daily drug cost of the medical unit to be monitored in the single evaluation cycle can be determined according to the unilateral average daily drug cost of the traditional Chinese medicine prescription in each day of the above single evaluation cycle, which may be referred to for convenience of description
  • the cumulative value of the average daily drug cost per party The cumulative value of the total number of days of drug use in the single evaluation period of the medical unit to be monitored can be determined according to the total number of days of the use of traditional Chinese medicine prescriptions for each day in the single evaluation cycle.
  • the average daily drug cost of the medical unit to be monitored is determined according to the cumulative value of the above-mentioned unilateral daily average drug cost, the cumulative value of the above-mentioned total days of drug use and the number of prescriptions in a single assessment cycle.
  • the unilateral average daily drug cost of the medical unit to be monitored (that is, the unilateral average daily drug cost of the medical unit to be monitored within a single evaluation period) can satisfy the following formula (3):
  • Unilateral daily average drug cost cumulative value of unilateral daily average drug cost / cumulative value of total days of drug use / number of prescriptions in a single assessment cycle.
  • the cumulative value of the average daily drug cost in the above formula (3) may be the average daily average of the unilateral daily prescriptions for each of the 7 single-day traditional Chinese medicine prescriptions within a week
  • the accumulated value of the total number of days of use of the drug in the above formula (3) may be the accumulated value of the total number of days of use of the drug of each single-day Chinese medicine prescription in the 7 single-day Chinese medicine prescriptions within a week.
  • S23 Determine the unilateral average daily drug cost threshold of the medical unit to be monitored according to the unit attribute information of the medical unit to be monitored.
  • the specific implementation manner of determining whether the medication of the medical unit to be monitored exceeds the standard according to the unilateral average daily drug cost of the medical unit to be monitored and the unilateral average daily drug cost threshold corresponding to the medical unit to be monitored can be found in the above The implementation provided by step S13 in the embodiment will not be repeated here.
  • the evaluation index thresholds of the drug monitoring standards and / or drug evaluation standards of each medical unit may also be determined based on the unit attribute information of each medical unit, For example, the daily drug cost per party does not exceed the upper limit.
  • the unit attribute information of the medical unit to be monitored includes one or more of the unit type, the region where the unit is located, the city where the unit is located, the unit drug supply channel, and the number of patients of the unit, which can be determined according to the actual application scenario. There are no restrictions here. For example, based on different medical units associated with parameters such as different regions, different cities, different drug supply channels, or different patient flows, the evaluation thresholds for drug monitoring may vary.
  • the upper limit of the daily drug cost per party may not be exceeded
  • the corresponding evaluation index threshold of the drug monitoring standard can be set to a higher evaluation index.
  • the upper limit of the daily drug cost per party can be set lower. That is, the threshold of the assessment index of the corresponding medication monitoring standard can be set to a lower assessment index.
  • the average daily drug cost of the medical unit to be monitored based on the above determination, combined with the threshold of the assessment index determined based on the unit attribute information of the medical unit to be monitored (that is, the upper limit of the daily drug cost per unit) Whether the medical unit's medication exceeds the standard, in other words, whether the average daily drug cost of the medical unit to be monitored is less than or equal to the upper limit of its corresponding daily drug cost. If the average daily drug cost of the medical unit to be monitored is less than or equal to the upper limit of the corresponding average daily drug cost of the corresponding medical unit, it can be determined that the medication of the medical unit to be monitored does not exceed the standard, otherwise the drug of the medical unit is excessive.
  • the average daily drug cost of the unilateral daily drug cost difference of the above-mentioned medical unit to be monitored is disclosed, so as to realize the prescription of the Chinese medicine for the medical unit to be monitored
  • the implementation method of the prescription drug for exceeding the drug cost risk control reference may be made to the implementation method provided in step S14 in the foregoing embodiment, and details are not described herein again.
  • the terminal device may feed back the medical unit's feedback when receiving the medical drug reimbursement and / or claim request for that day
  • the prescription drug cost of the day refuses to be reimbursed or settled, and the medical unit can be prompted to self-control the daily average daily drug cost of the prescription to achieve the prescription risk control of the medical unit's drug cost exceeding the standard.
  • the terminal device may calculate The difference between the unit's average daily drug cost and the above-mentioned average daily drug cost threshold.
  • the terminal device receives the medical expense reimbursement and / or claim request from the medical unit to be monitored, it can target the difference between the unilateral daily average drug cost of the medical unit to be monitored and the above unilateral daily average drug cost threshold.
  • the medical cost of the single-day prescription of the medical unit to be monitored is refused to be reimbursed or settled in order to carry out prescription risk control for the medical unit that exceeds the medical cost of the prescription of traditional Chinese medicine.
  • the terminal device determines that the prescription of the traditional Chinese medicine within a certain evaluation cycle (eg, one day or one week, etc.) of the medical unit to be monitored exceeds the standard, for example, within a certain evaluation cycle of the medical unit to be monitored
  • a certain evaluation cycle e.g. one day or one week, etc.
  • the terminal device can be after the evaluation cycle (the daily average drug cost of a single-day prescription exceeds a certain day, such as Monday)
  • the report of the single-day daily drug cost exceeding standard for the evaluation cycle is sent to the medical unit to be monitored.
  • the unilateral daily average drug cost exceeding report is used to prompt the medical unit to be monitored to exceed the standard within the evaluation period, and can remind the medical unit to be monitored if it is within the next evaluation period or multiple consecutive evaluation periods within the specified time If the unilateral average daily drug cost still exceeds the standard, the medical unit to be monitored will be punished for the unilateral average daily drug cost exceeding the standard.
  • the above-mentioned punishment includes the refusal or reimbursement of the unilateral average daily drug cost of the medical unit to be monitored that exceeds the standard, or the refusal or reimbursement of the unilateral average daily drug cost of the medical unit to be monitored, etc.
  • the above-mentioned unilateral daily average drug cost exceeding standard report is used to prompt the medical unit to be monitored to self-control the unilateral daily average drug cost to realize the risk control of exceeding the medical cost of the medical unit to be monitored.
  • the medicine monitoring operation methods for the prescriptions of traditional Chinese medicine in various medical units are various, which can not only improve the accuracy of the medicine monitoring of the traditional Chinese medicine decoction pieces of the medical unit, but also improve the reliability of the medicine monitoring of the medical unit. At the same time, it can also enhance the operational flexibility of the medical unit's medication monitoring. Furthermore, the reliability of the risk control of exceeding the standard of medication can be improved, the medication controllability of the prescription of the medical unit can be improved, so that the effective utilization rate of medical resources can be improved and the applicability is stronger.
  • FIG. 3 is a schematic structural diagram of an embodiment of a data processing-based risk control device for prescription medicine cost based on data processing provided by an embodiment of the present application.
  • the data processing risk control device for prescription drugs of traditional Chinese medicine provided by embodiments of the present application includes:
  • the data obtaining unit 31 is used to obtain a Chinese medicine prescription of the medical unit to be monitored, and the above Chinese medicine prescription includes at least one Chinese medicine decoction piece.
  • the medicine information processing unit 32 is configured to obtain the Chinese medicine decoction drug information of each Chinese medicine decoction in the Chinese medicine prescription obtained by the data obtaining unit 31, and determine the unilateral average daily drug cost of the medical unit to be monitored based on the Chinese medicine decoction drug information.
  • the medication evaluation unit 33 is used to determine whether the medication of the TCM decoction pieces of the medical unit to be monitored exceeds the standard according to the unilateral average daily drug cost determined by the drug information processing unit 32 and the unilateral average daily drug cost threshold corresponding to the medical unit to be monitored .
  • the medication risk control unit 34 is used to conduct the medical unit to be monitored based on the unilateral average daily drug cost determined by the drug information processing unit 32 when the medication evaluation unit 33 determines that the medication of the TCM decoction of the medical unit to be monitored exceeds the standard Risk control of excessive cost of Chinese herbal medicines.
  • the above-mentioned medication risk control unit 34 is used to:
  • the unit controls the use of Chinese herbal medicines in prescriptions of Chinese medicines to achieve the risk control of excessive drug costs for Chinese medicines; and / or
  • the request for reimbursement of the drug cost is rejected in order to realize the risk control of exceeding the standard for the cost of drugs prescribed by Chinese medicine.
  • one of the above-mentioned Chinese medicine decoction pieces includes at least one Chinese medicine decoction piece, and the above-mentioned Chinese medicine decoy piece medicine information includes at least the medicine cost and the number of days the medicine is used;
  • the total number of days of use of the above-mentioned traditional Chinese medicine prescription is determined according to the number of days of use of each of the above-mentioned Chinese herbal medicines, and the unilateral average daily drug cost of the medical unit to be monitored is determined based on the above-mentioned total cost of the medicine and the total number of days of the above-mentioned drug use.
  • Unilateral average daily drug cost total drug cost / total days of drug use.
  • the above-mentioned drug information processing unit 32 is used to:
  • the cumulative value of the drug cost of each piece of Chinese medicine decoction in the above Chinese medicine prescription is determined as the total drug cost of the above Chinese medicine prescription.
  • the data acquisition unit 31 is used to:
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes the single traditional Chinese medicine prescription of the medical unit to be monitored, or all the traditional Chinese medicine prescriptions of the medical unit to be monitored within a single assessment cycle, the duration of the single assessment cycle is one day or greater than one day.
  • the data acquisition unit 31 is used to:
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes the single traditional Chinese medicine prescription of the medical unit to be monitored, or all the traditional Chinese medicine prescriptions of the medical unit to be monitored within a single assessment cycle, the duration of the single assessment cycle is one day or greater than one day.
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes all the traditional Chinese medicine prescriptions of the medical unit to be monitored within a single day;
  • the above medicine information processing unit 32 is also used for:
  • the information of the Chinese herbal medicines at least includes the medicine cost and the days of use of the Chinese herbal medicines;
  • the unilateral daily drug cost of the above-mentioned medical unit to be monitored meets:
  • Unilateral average daily drug cost total drug / total days of drug use / number of prescriptions.
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes all the traditional Chinese medicine prescriptions of the medical unit to be monitored in a single assessment period of multiple days;
  • the above medicine information processing unit 32 is also used for:
  • the above Chinese medicine decoction drug information includes at least the Chinese medicine decoction drug cost and Days of drug use;
  • the total number of days of drug use on any one day is the sum of the number of days of drug use on the traditional Chinese medicine decoction in any one-day traditional Chinese medicine prescription.
  • the above-mentioned drug information processing unit 32 is used to:
  • the unilateral daily drug cost of the above-mentioned medical unit to be monitored meets:
  • Unilateral daily average drug cost cumulative value of a single daily unilateral daily drug cost / cumulative value of total days of drug use / the number of prescriptions in a single assessment cycle.
  • the above-mentioned medication evaluation unit 33 is further used to:
  • the unit attribute information of the medical unit to be monitored determine the daily average drug cost threshold of the medical unit to be monitored
  • the unit attribute information of the medical unit to be monitored includes one or more of the unit type, the region where the unit is located, the city where the unit is located, the drug supply channel of the unit, and the number of patients of the unit.
  • the above-mentioned medication evaluation unit 33 is used to:
  • the above-mentioned data processing-based Chinese medicine prescription drug cost risk control device may execute the implementation manners provided by the above steps in FIGS. 1 to 2 through various built-in functional modules.
  • the above-mentioned data processing-based Chinese medicine prescription drug cost risk control device may be the terminal device described in each of the foregoing embodiments, which is not limited herein.
  • the medication monitoring operation method for the Chinese medicine prescription of each medical unit based on the medication monitoring device is diverse, which can improve the accuracy of the medication monitoring of the Chinese medicine decoction pieces of the medical unit and improve the reliability of the medication monitoring of the medical unit At the same time, it can also enhance the operational flexibility of the medical unit's medication monitoring. Furthermore, the reliability of the risk control of exceeding the standard of medication can be improved, the medication controllability of the prescription of the medical unit can be improved, so that the effective utilization rate of medical resources can be improved and the applicability is stronger.
  • FIG. 4 is a schematic structural diagram of an embodiment of a terminal device provided by an embodiment of the present application.
  • the terminal device in this embodiment may include: one or more processors 401 and a memory 402.
  • the processor 401 and the memory 402 are connected via a bus 403.
  • the memory 402 is used to store a computer program, and the computer program includes program instructions, and the processor 401 is used to execute the program instructions stored in the memory 402.
  • the processor 401 is configured to call the program instruction to perform the following operations:
  • the Chinese medicine prescription of the medical unit to be monitored includes at least one Chinese medicine decoction
  • the above-mentioned unilateral daily average drug cost and the above-mentioned unilateral daily average drug cost threshold corresponding to the medical unit to be monitored determine whether the use of traditional Chinese medicine decoction in the medical unit to be monitored exceeds the standard;
  • the risk of exceeding the standard of the medicine cost of the Chinese medicine to the monitored unit shall be controlled based on the above-mentioned unilateral average daily drug cost.
  • the foregoing processor 401 is used to:
  • the unit controls the use of Chinese herbal medicines in prescriptions of Chinese medicines to achieve the risk control of excessive drug costs for Chinese medicines; and / or
  • the request for reimbursement of the drug cost is rejected in order to realize the risk control of exceeding the standard for the cost of drugs prescribed by Chinese medicine.
  • one of the above-mentioned Chinese medicine decoction pieces includes at least one Chinese medicine decoction piece, and the above-mentioned Chinese medicine decoction medicine information includes at least the drug cost and the number of days of use of the drug; the above-mentioned processor 401 is used to:
  • the total number of days of use of the above-mentioned traditional Chinese medicine prescription is determined according to the number of days of use of each of the above-mentioned Chinese medicine decoction pieces, and the unilateral average daily drug cost of the medical unit to be monitored is determined based on the above-mentioned total cost of the medicine and the total number of days of the drug usage.
  • Unilateral average daily drug cost total drug cost / total days of drug use.
  • the foregoing processor 401 is configured to:
  • the cumulative value of the drug cost of each piece of Chinese medicine decoction in the above Chinese medicine prescription is determined as the total drug cost of the above Chinese medicine prescription.
  • the foregoing processor 401 is configured to:
  • the foregoing processor 401 is configured to:
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes the single traditional Chinese medicine prescription of the medical unit to be monitored, or all the traditional Chinese medicine prescriptions of the medical unit to be monitored within a single assessment cycle, and the duration of the single assessment cycle includes one day or more than one day.
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes all traditional Chinese medicine prescriptions of the medical unit to be monitored within a single day;
  • the above processor 401 is also used for:
  • the information of the Chinese herbal medicines at least includes the medicine cost and the days of use of the Chinese herbal medicines;
  • the unilateral daily drug cost of the above-mentioned medical unit to be monitored meets:
  • Unilateral average daily drug cost total drug / total days of drug use / number of prescriptions.
  • the traditional Chinese medicine prescription of the medical unit to be monitored includes all the traditional Chinese medicine prescriptions of the medical unit to be monitored in a single assessment period of multiple days;
  • the above processor 401 is also used for:
  • the above Chinese medicine decoction drug information includes at least the Chinese medicine decoction drug cost and Days of drug use;
  • the total number of days of drug use on any one day is the sum of the number of days of drug use on the traditional Chinese medicine decoction in any one-day traditional Chinese medicine prescription.
  • the foregoing processor 401 is used to:
  • the unilateral daily drug cost of the above-mentioned medical unit to be monitored meets:
  • Unilateral daily average drug cost cumulative value of a single daily unilateral daily drug cost / cumulative value of total days of drug use / the number of prescriptions in a single assessment cycle.
  • the average daily drug cost of the medical unit to be monitored above meets:
  • Unilateral average daily drug cost total cost of periodic drugs / total days of periodic drugs / number of prescriptions in a single evaluation cycle
  • the total cost of medicines in the above cycle may be the total cost of medicines of all traditional Chinese medicine pieces included in all traditional Chinese medicine pieces included in the prescription of all traditional Chinese medicines in a single evaluation period
  • the total number of days of use of the above-mentioned periodic medicines may be a single evaluation period
  • the foregoing processor 401 is further used to:
  • the unit attribute information of the medical unit to be monitored determine the daily average drug cost threshold of the medical unit to be monitored
  • the unit attribute information of the medical unit to be monitored includes one or more of the unit type, the region where the unit is located, the city where the unit is located, the drug supply channel of the unit, and the number of patients of the unit.
  • the foregoing processor 401 is used to:
  • the processor 401 may be a central processing unit (CPU), and the processor may also be other general-purpose processors, digital signal processors (DSPs), and dedicated integrations. Circuit (application specific integrated circuit, ASIC), ready-made programmable gate array (field-programmable gate array, FPGA) or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components, etc.
  • the general-purpose processor may be a microprocessor or the processor may be any conventional processor or the like.
  • the memory 402 may include a read-only memory and a random access memory, and provide instructions and data to the processor 401. A portion of the memory 402 may also include non-volatile random access memory. For example, the memory 402 may also store device type information.
  • the above-mentioned terminal device may execute the implementation manners provided by the steps in FIG. 1 to FIG. 2 through the function modules of the built-in processor 401.
  • the above-mentioned terminal device may execute the implementation manners provided by the steps in FIG. 1 to FIG. 2 through the function modules of the built-in processor 401.
  • the implementation manners provided by the above steps And will not be repeated here.
  • the monitoring methods of the medication monitoring of the traditional Chinese medicine prescriptions of various medical units are diverse, which can not only improve the accuracy of the monitoring of the traditional Chinese medicine decoction pieces of the medical unit, but also improve the reliability of the medical monitoring of the medical unit.
  • the operational flexibility of the unit's medication monitoring Furthermore, the reliability of the risk control of exceeding the standard of medication can be improved, the medication controllability of the prescription of the medical unit can be improved, so that the effective utilization rate of medical resources can be improved and the applicability is stronger.
  • Embodiments of the present application also provide a computer-readable storage medium that stores a computer program, and the computer program includes program instructions, which are executed by a processor to implement the steps in FIGS. 1 to 2.
  • the data processing risk control method for prescription medicines based on data processing provided in the above can be referred to the implementation provided in the above steps, which will not be repeated here.
  • the foregoing computer-readable storage medium may be the data processing-based Chinese medicine prescription drug cost risk control device provided in any of the foregoing embodiments or the internal storage unit of the foregoing terminal device, such as the hard disk or memory of the electronic device.
  • the computer-readable storage medium may also be an external storage device of the electronic device, such as a plug-in hard disk equipped on the electronic device, a smart memory card (smart media card, SMC), a secure digital (SD) card, Flash card (flash card), etc.
  • a plug-in hard disk equipped on the electronic device such as a plug-in hard disk equipped on the electronic device, a smart memory card (smart media card, SMC), a secure digital (SD) card, Flash card (flash card), etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种基于数据处理的中药处方药品费用风险控制方法及装置，该方法包括：获取待监控医疗单位的中药处方，中药处方中包括至少一剂中药饮片；获取中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定待监控医疗单位的单方日均药品费用；根据单方日均药品费用和待监控医疗单位对应的单方日均药品费用阈值，确定待监控医疗单位的中药饮片的用药是否超标。若待监控医疗单位的中药饮片的用药超标，则基于上述单方日均药品费用对待监控医疗单位进行中药饮片药品费用超标的风险控制。可提高对医疗单位的中药饮片的用药监控准确性，提高对医疗单位的用药监控的可靠性，适用性强。

Description

基于数据处理的中药处方药品费用风险控制方法及装置
本申请要求于2018年10月22日提交中国专利局、申请号为201811232863.6、申请名称为“基于数据处理的中药处方药品费用风险控制方法及装置”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本申请涉及医疗技术领域，尤其涉及一种基于数据处理的中药处方药品费用风险控制方法及装置。
背景技术
当前为了规范各个医疗单位的用药标准，规避大处方行为，从而避免药品的滥用和浪费，起到合理施治的目的，各式各样的用药监控机制应运而生。各式各样的用药监控机制用于对各个医疗单位进行用药监控，包括但不限于各个医院、各个医院的科室、各个诊所乃至各个医师等医疗单位(或者医疗单位的代表)进行用药监控。
现有技术中，对于各个医疗单位的用药标准的评价主要是采用次均中药处方标准，也就是将每个中药处方的中药饮片日均费用(简称次均中药处方费用)作为各个医疗单位的用药评价标准。其中，上述次均中药处方费用的用药评价标准是采用处方总额除以处方数量的计算方式来计算得到。现有技术采用次均中药处方费用作为各个医疗单位的中药处方的用药评价标准导致各个医疗单位为了规避大处方行为被考核，通常会采用缩减处方天数来减低次均中药处方费用，或者通过分解处方的方式将单个处方总额较大的大处方分解为多个单个处方总额较小的小处方等方式来降低次均中药处方费用，从而规避大处方的监控。现有技术的用药评价方式使得各个医疗单位的用药监控的漏洞较大，对各个医疗单位的用药评价的准确率低，适用性弱。
发明内容
本申请实施例提供一种基于数据处理的中药处方药品费用风险控制方法及装置，操作简单，可提高对医疗单位的中药处方的用药监控精度，提高对医疗单位的用药监控的可靠性，适用性更强。
第一方面，本申请实施例提供了一种基于数据处理的中药处方药品费用风险控制方法，该方法包括：
获取待监控医疗单位的中药处方，上述中药处方中包括至少一剂中药饮片；
获取上述中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定上述待监控医疗单位的单方日均药品费用；
根据上述单方日均药品费用和上述待监控医疗单位对应的单方日均药品费用阈值，确定上述待监控医疗单位的中药饮片的用药是否超标；
若上述待监控医疗单位的中药饮片的用药超标，则基于上述单方日均药品费用对上述待监控医疗单位进行中药饮片药品费用超标的风险控制。
第二方面，本申请实施例提供了一种基于数据处理的中药处方药品费用风险控制装置，该装置包括：
数据获取单元，用于获取待监控医疗单位的中药处方，上述中药处方中包括至少一剂 中药饮片；
药品信息处理单元，用于获取上述数据获取单元获取的上述中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定上述待监控医疗单位的单方日均药品费用；
用药评价单元，用于根据上述药品信息处理单元确定的上述单方日均药品费用，和上述待监控医疗单位对应的单方日均药品费用阈值确定上述待监控医疗单位的中药饮片的用药是否超标；
用药风险控制单元，用于在上述用药评价单元确定上述待监控医疗单位的中药饮片的用药超标时，基于上述药品信息处理单元确定的上述单方日均药品费用对上述待监控医疗单位进行中药饮片药品费用超标的风险控制。
第三方面，本申请实施例提供了一种终端设备，该终端设备包括处理器和存储器，该处理器和存储器相互连接。该存储器用于存储支持该终端设备执行上述第一方面和/或第一方面任一种可能的实现方式提供的方法的计算机程序，该计算机程序包括程序指令，该处理器被配置用于调用上述程序指令，执行上述第一方面和/或第一方面任一种可能的实施方式所提供的方法。
第四方面，本申请实施例提供了一种计算机可读存储介质，该计算机可读存储介质存储有计算机程序，该计算机程序包括程序指令，该程序指令当被处理器执行时使该处理器执行上述第一方面和/或第一方面任一种可能的实施方式所提供的方法。
基于本申请实施例提供的方法实现对各医疗单位的用药监控操作简单，可提高对医疗单位的用药监控的准确性，提高对医疗单位的用药监控的可靠性，提高医疗资源的有效利用率，适用性更强。
附图说明
图1是本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法的一流程示意图；
图2是本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法的另一流程示意图；
图3是本申请实施例提供的基于数据处理的中药处方药品费用风险控制装置的实施例结构示意图；
图4是本申请实施例提供的终端设备的实施例结构示意图。
具体实施方式
本申请实施例提供了一种基于数据处理的中药处方药品费用风险控制方法，可基于各个医院、各个医院的科室、各个诊所乃至各个医师等医疗单位(或者医疗单位的代表(或称团队))的单方日均药品费用(即单个中药处方的单方日均药品费用)来评价各个医疗单位(包括医院、科室、诊所或者医师)的中药处方的用药是否超标(或称合理)，并可基于医疗单位的中药处方的用药情况对医疗单位的处方进行单方日均药品费用超标的公示，和/或拒绝单方日均药品费用超标对应的中药饮片药品费用报销等中药处方的中药饮片药品费用超标的风险控制，以避免医疗资源的浪费。为方便描述，上述各个医院、各个医院的科室、各个诊所乃至各个医师等等医疗单位或者医疗单位的代表所表示的考核维度将以医疗 单位的这个考核维度为例进行说明，下面不再赘述。
本申请实施例所提供的中药处方可包括各个医疗单位的各个医师针对各个病患的病症所开具的中药处方，或称各个医师针对各个病患的病症所开具的中药药方，或称处方笺等，在此不做限制。为方便描述，下面将以处方为例进行说明。通常来讲，各个医疗单位的各个医师所开具的处方中可包括但不限于处方开具时间、处方编号、科室编号、病患个人信息、中药饮片的药品详情以及医师签字，具体可根据实际应用场景确定，在此不做限制。换句话说，无论是单个处方总额较大的大处方，还是单个处方总额较小的小处方，或者其他更多表现形式的处方，每个处方中均会有医疗单位开具的中药饮片的药品详情，包括但不限于中药饮片的名称、中药饮片的金额、中药饮片的使用方式以及中药饮片的药品使用天数等。因此无论是大处方还是小处方还是其他，均离不开中药饮片的药品详情。因此，基于各个医疗单位的单方日均药品费用实现对各个医疗单位的中药处方的用药进行评价从而实现对各个医疗单位的用药监控，操作简单并且可更好地、更加全面地覆盖到对医疗单位的各个中药处方的用药监控。同时基于医疗单位的单方日均药品费用实现对各个医疗单位的用药监控更加准确到位，从而可提高对各个医疗单位的用药监控的准确率，进而可提高基于各个医疗单位的中药处方用药情况对各个医疗单位的中药处方进行单方日均药品费用超标的公示、和/或拒绝单方日均药品费用超标对应的药品费用报销等中药处方的中药饮片药品费用超标的风险控制的可靠性，可提高该医疗单位开方的用药可控性，从而可提高医疗资源的有效利用率，适用性更高。
这里，中药饮片是中药材经过按中医药理论、中药炮制方法，经过加工炮制后的可直接用于中医临床的中药。由此表明，中药材、中药饮片并没有绝对的界限，中药饮片包括了部分经产地加工的中药切片，原形药材饮片以及经过切制、炮炙的饮片。为方便描述，下面将以中药饮片为例进行说明。常见的中药饮片的品种包括但不限于：1、干姜；2、炮姜；3、姜炭；4、大黄；5、酒大黄；6、熟大黄；7、大黄炭；8、栀子；9、焦栀子；10、炒栀子；11、黄芪；12、炙黄芪；13、黄连；14、酒黄连；15、姜黄连；16、萸黄连；17、麻黄；18、炙麻黄；19、丹参；20、酒丹参；21、何首乌；22、制何首乌；23、甘草；24、炙甘草；25、石膏；26、煅石膏；27、白术；28、炒白术；29、焦白术；30、赤芍；31、白芍；32、炒白芍；33、酒白芍；34、生地黄；35、熟地黄；36、当归；37、酒当归；38、槟榔；39、焦槟榔；40、延胡索；41、醋延胡索；42、槐花；43、槐花炭；44、黄芩；45、酒黄芩；46、三七粉；47、红参；48、冰片；49、红粉；50、轻粉；51、玄明粉；52、芒硝；53、青黛；54、滑石粉；55、赭石；56、煅赭石；57、芦荟；58、儿茶；59、制川乌；60、制草乌；61、黑顺片；62、白附片；63、淡附片；64、炮附片；65、巴豆霜；66、千金子霜；67、马钱子粉；68、米斑蝥；69、朱砂；70、雄黄；71、炒谷芽；72、煅牡蛎；73、炒稻芽；74、醋香附；75、醋柴胡；76、酒肉苁蓉；77、煅龙齿；78、煅石决明；79、醋龟甲；80、焦六神曲。上述中药饮片仅是示例，并非穷举，具体可根据实际应用场景需求确定，在此不做限制。
本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法可由药品监督管理局、卫生委员会、卫生与健康委员会以及医疗理赔单位等用药监控单位所关联的终端设备执行，例如上述用药监控单位用于对各个医疗单位进行用药监控的客户端和/或人机交互 设备等，在此不做限制。为方便描述，下面将以终端设备为例进行说明。
实施例一：
参见图1，图1是本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法的一流程示意图。本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法，可通过如下步骤S11至S14中各个步骤所提供的实现方式进行说明。
S11，获取待监控医疗单位的中药处方。
在一些可行的实施方式中，上述待监控医疗单位可为用药监控单位所监控的任一医疗单位，具体可根据实际应用场景确定，在此不做限制。换句话说，任一医疗单位都可能被用药监控单位作为监控对象，因此被选中的监控对象则可为待监控医疗单位。为方便描述，下面将以待监控医疗单位为例进行说明。
在一些可行的实施方式中，上述医疗单位的中药处方可包括待监控医疗单位在任一日的单日时间内所产生的所有中药处方，包括但不限于单日时间内医院的所有科室所有医师所开具的所有中药处方、单日时间内医院的某一个科室的所有医师所开具的所有中药处方，或者单日时间内医院的某一个科室的某一个医师所开具的所有中药处方中的任一种情况。其中，上述中药处方所表示的具体情况根据实际应用场景中对医疗单位进行用药评价的考核维度确定，在此不做限制。本申请实施例提供的方法可基于上述各种表现形式的中药处方计算任一中药处方(为方便描述可简称单方)中所包括中药饮片的单方日均药品费用，进而可基于任一中药处方的单方日均药品费用对医疗单位的用药进行评价。基于单方中所包括的中药饮片的单方日均药品费用对医疗单位进行用药标准评价，粒度更细，用药监控更加严格有效。为方便描述，下面将以单个中药处方所包括的中药饮片的单方日均药品费用为例进行说明，以下简称单方日均药品费用。
通俗来讲，针对中药饮片的中药处方(为方便描述可简称处方)来说，一个处方可以包括一剂或者多剂中药饮片，其中每剂药中药饮片中可包括一个或者多个品种(或称种类)的中药饮片。换句话说，就是一个处方上可以包括一剂或者多剂的中药饮片，其中每剂中药饮片中包括一个或者多个品种的中药饮片，这多个品种的中药饮片中每个品种的中药饮片都有各自的单价，并且该在处方中均有各自的剂量。一剂中药饮片中的所有品种的中药饮片混合在一起使用，一剂中药饮片中所有品种的中药饮片的服用方式是混合之后一起放入砂锅或者搪瓷盘进行煎煮，最后得到一碗药汤。因此，单个处方中所有中药饮片的药品使用天数就是该处方中每剂中药饮片的药品使用天数累加值，为方便描述也可称为药品使用总天数为例进行说明等。比如，单个处方中所包括的中药饮片有M剂，每剂中药饮片的使用天数是一天，则上述处方中所包括的中药饮片的药品使用总天数则为M(即M*1)天。
在一些可行的实施方式中，终端设备可与待监控医疗单位的数据系统对接，获取待监控医疗单位的数据系统准入资格，进而可基于待监控医疗单位的数据系统准入资格从待监控医疗单位的数据系统中获取待监控医疗单位的中药处方。可选的，终端设备也可基于待监控医疗单位所提供了医疗理赔数据，从医疗理赔数据中筛选得到医疗单位的中药处方等处方数据。可选的，终端设备也可基于大数据分析，从各个医疗单位的病患就诊记录中筛选得到待监控医疗单位的中药处方等处方数据，等等。终端设备可基于上述数据获取方式之外的任一数据获取路径获取得到待监控医疗单位的中药处方，具体可根据实际应用场景 确定，在此不做限制。
可以理解，这里待监控医疗单位的中药处方中任一处方上均可包括该处方中所开药品的药品详情，包括但不限于药品名称、药品费用，药品使用方式(或称药品服用方式等)以及药品使用天数，具体可根据实际应用场景确定，在此不做限制。
S12，获取上述中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定上述待监控医疗单位的单方日均药品费用。
在一些可行的实施方式中，终端设备获取得到待监控医疗单位的中药处方(比如单个中药处方，或简称单方)之后，可获取上述单个中药处方中所包括的各剂中药饮片的中药饮片药品信息，包括但不限于中药饮片的药品费用和药品使用天数。基于待监控医疗单位的单个中药处方可以获取上述单个中药处方中各剂中药饮片所包括的各种中药饮片的药品费用，根据上述各种中药饮片的药品费用确定上述单个中药处方的药品总费用。其中，上述单个中药处方中中药饮片的药品总费用为单个中药处方一剂或者多剂中药饮片中各剂中药饮片的费用累加值。其中，每剂中药饮片的费用是该剂中药饮片中每种中药饮片的费用累加值，单剂中药饮片中任一种中药饮片的费用为该种中药饮片的单价与该种中药饮片在单剂的剂量的乘积。可选的，上述单个中药处方的药品总费用也可以是单个中药处方中所包括的各种中药饮片的药品费用的累计值，其中，单种中药饮片的药品费用为该中药饮片的单价与该中药饮片在单个中药处方中的剂量总和的乘积，具体可根据实际应用场景确定单个中药处方的药品总费用，在此不做限制。基于一剂或者多剂的中药饮片中各剂中药饮片的药品费用的累加值可得到该中药处方中所有中药饮片的药品总费用。
在一些可行的实施方式中，根据中药饮片中各剂中药饮片的药品使用天数可确定中药处方的药品使用总天数，根据上述药品总费用和上述药品使用总天数可确定上述待监控医疗单位的单方日均药品费用。上述单个中药处方的中药饮片的药品使用总天数为一剂或者多剂中药饮片中各剂中药饮片的药品使用天数累加值，具体可参见上述步骤S11中所描述的实现方式，在此不做限制。待监控医疗单位的单个中药处方的单方日均药品费用表示待监控医疗单位单个中药处方中所有中药饮片的每日平均药品费用，其中，上述待监控医疗单位的单个中药处方的单方日均药品费用可基于如下公式(1)计算得到：
公式(1)：单方日均药品费用＝中药饮片的药品总费用/中药饮片的药品使用总天数。
其中，上述公式(1)中，上述中药饮片的药品总费用为单个中药处方一剂或者多剂中药饮片的费用累加值，其中，每剂中药饮片的费用是该剂中药饮片中所包括的所有中药饮片中每种中药饮片的费用的累加。上述中药饮片的药品使用总天数指该中药处方中所包括的一剂或者多剂中药饮片中各剂中药饮片的使用天数的累加值。
S13，根据上述单方日均药品费用和上述待监控医疗单位对应的单方日均药品费用阈值，确定上述待监控医疗单位的中药饮片的用药是否超标。
在一些可行的实施方式中，针对不同医疗单位进行用药监控时，可预先设定各个医疗单位的用药监控标准和/或用药评价标准的考核指标阈值，例如单方日均药品费用的不超标上限(或称单方日均药品费用上限)等。例如，针对待监控医疗单位进行用药监控时，可基于待监控医疗单位的历史用药记录或者药品使用政策等信息设定待监控医疗单位对应的单方日均药品费用上限，进而可基于上述确定的待监控医疗单位的单方日均药品费用，结 合该待监控医疗单位对应的考核指标阈值(即单方日均药品费用上限)确定该医疗单位的用药是否超标。换句话说，就是该待监控医疗单位的单方日均药品费用是否小于或者等于其对应的单方日均药品费用上限。若该待监控医疗单位的单方日均药品费用小于或者等于其对应的单方日均药品费用上限，则可确定待监控医疗单位的用药是不超标的。若待监控医疗单位的单方日均药品费用大于其对应的单方日均药品费用上限，则可确定待监控医疗单位的用药是超标的，即待监控医疗单位的药品费用超标。
S14，若上述待监控医疗单位的中药饮片的用药超标，则基于上述单方日均药品费用对上述待监控医疗单位进行中药饮片药品费用超标的风险控制。
在一些可行的实施方式中，当上述待监控医疗单位的用药超标，例如待监控医疗单位的单方日均药品费用大于单方日均药品费用阈值时，可确定上述待监控医疗单位的单方日均药品费用中超出单方日均药品费用阈值部分的单方日均药品费用差值。基于上述单方日均药品费用差值可将上述单方日均药品费用和/或上述单方日均药品费用差值进行公示，基于公示的单方日均药品费用和/或单方日均药品费用差值提示待监控医疗单位的医师控制中药处方的开方用药，避免该待监控医疗单位的医师在开方过程中随意用药造成药品等医疗资源的浪费，实现对待监控医疗单位的中药处方的药品费用超标风险控制。可选的，基于上述单方日均药品费用和/或单方日均药品费用差值可在该待监控医疗单位的单位大厅公告界面(例如单位大厅的消息公告显示屏)上进行公示或者在用药监管单位所出的医疗单位用药监控日报上进行公示，以控制待监控医疗单位及其各个医师的中药处方开方用药，避免待监控医疗单位的中药处方的单方日均药品费用持续超标带来的医疗资源浪费，实现对该待监控医疗单位的用药超标风险控制。可选的，基于上述单方日均药品费用和/或单方日均药品费用差值也可在该待监控医疗单位的各个科室的信息公告界面上进行公示，和/或在该待监控医疗单位的各个医师的开方工具的首页上进行公示等，具体可根据实际应用场景确定，在此不做限制。
基于本申请实施例提供的方法实现对各医疗单位的中药处方的用药监控操作简单，可提高对医疗单位的中药处方的用药监控准确性，提高对医疗单位的用药监控的可靠性，进而可提高用药处方的药品费用超标风险控制的可靠性，提高该医疗单位的中药处方的开方用药的可控性，从而可提高医疗资源的有效利用率，适用性更强。
实施例二：
参见图2，图2是本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法的另一流程示意图。本申请实施例提供的基于数据处理的中药处方药品费用风险控制方法可实现对待监控医疗单位在单个考核周期内的用药情况进行监控，该方法可通过如下步骤S21至S25中各个步骤所提供的实现方式进行说明。
S21，获取待监控医疗单位的中药处方。
在一些可行的实施方式中，上述获取待监控医疗单位的中药处方的实现方式可参见上述实施例中步骤S11所提供的实现方式，在此不再赘述。
可选的，在一些可行的实施方式中，上述医疗单位的中药处方还可包括待监控医疗单位在单个考核周期内产生的所有中药处方，其中上述单个考核周期为一日或者大于一日，例如一个星期、一个月、一个季度或者一年等，在此不做限制。为方便描述，上述待监控 医疗单位在单个考核周期内所产生的所有中药处方可以单考核周期处方为例进行说明。
可选的，上述医疗单位的单考核周期处方可以是指医疗单位的任一考核周期内所开具的所有处方，包括但不限于单个考核周期内医院的所有科室所有医师所开具的所有处方、单个考核周期内医院的某一个科室的所有医师所开具的所有处方，或者单个考核周期内医院的某一个科室的某一个医师所开具的所有处方中的任一种情况。其中，上述单考核周期处方所表示的具体情况根据实际应用场景中对医疗单位进行用药监控的考核维度(例如针对医疗单位进行用药监控、针对医疗单位的某一个科室进行用药监控或者针对医疗单位的某一个科室的某一个医师进行用药监控等)确定，在此不做限制。为方便描述，下面将以单个考核周期内医院的所有科室所有医师所开具的所有处方为例进行说明，以下简称单考核周期处方。
可以理解，这里待监控医疗单位的单考核周期处方中所包括的任一中药处方上均可包括该中药处方中所包括的中药饮片的药品详情，包括但不限于药品名称、药品费用，药品使用方式以及药品使用天数，具体可根据实际应用场景确定，在此不做限制。
S22，获取上述中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定上述待监控医疗单位的单方日均药品费用。
在一些可行的实施方式中，上述基于待监控医疗单位的中药处方所包括的各剂中药饮片的中药饮片药品信息确定待监控医疗单位的单方日均药品费用的具体实现方式可参见上述实施例中步骤S12所提供的实现方式，在此不再赘述。
可选的，在一些可行的实施方式中，基于上述待监控医疗单位的中药处方的单方日均药品费用还可处理得到指定时间段内待监控医疗单位的单方日均药品费用，例如，一日，一个星期，一个月，一个季度或者一年的单方日均药品费用等。为方便描述，下面可以一个星期作为一个考核周期，以一个星期的单方日均药品费用为例进行说明，简称单考核周期处方的单方日均药品费用。
可选的，单考核周期处方的单方日均药品费用可满足如下公式(2):
公式(2)：单方日均药品费用＝周期药品总费用/周期药品使用总天数/单个考核周期的处方数量。
其中，在上述公式(2)中周期药品总费用可以是单个考核周期内的所有中药处方中所包括的所有中药饮片的药品费用累加得到的所有中药饮片的药品总费用，上述周期药品使用总天数可以是单考核周期处方所包括的所有中药饮片中每个中药饮片的药品使用天数的累加值。
可选的，在一些可行的实施方式中，基于待监控医疗单位的单考核周期处方中所包括的中药饮片的药品信息，可获取单个考核周期内任一日的任一单日中药处方，并获取任一单日的中药处方中所包括的各中药饮片的中药饮片药品信息，其中中药饮片药品信息中包括但不限于药品费用和药品使用天数。根据任一单日的中药处方所包括的各中药饮片的药品费用、药品使用天数和处方数量确定待监控医疗单位任一日中药处方的单方日均药品费用。其中，上述待监控医疗单位的任一日的单方日均药品费用可参见上述实施例中公式(2)对应的实现方式，在此不再赘述。此外，基于待监控医疗单位在单个考核周期内每日的中药处方中所包括的各中药处方的药品使用天数可确定每日的所有中药处方中的药品使用总 天数，进而可基于每日的所有中药处方的药品使用总天数确定待监控医疗单位的单考核周期处方中所包括的所有中药饮片的药品使用总天数。其中，待监控医疗单位在单个考核周期内的任一日的中药饮片的药品使用总天数为任一单日的所有中药处方中所包括的各中药饮片的药品使用天数的总和。根据上述待监控医疗单位在单个考核周期内各日的中药处方的单方日均药品费用和药品使用总天数可确定待监控医疗单位在单个考核周期内的单方日均药品费用。
在一些可行的实施方式中，根据上述单个考核周期内各日的中药处方的单方日均药品费用可确定待监控医疗单位在单个考核周期的单方日均药品费用的累加值，为方便描述可简称单方日均药品费用累加值。根据上述单个考核周期内各日的中药处方的药品使用总天数可确定待监控医疗单位在单个考核周期内的药品使用总天数的累加值，为方便描述可简称药品使用总天数累加值。根据上述单方日均药品费用累加值、上述药品使用总天数累加值和单个考核周期的处方数量确定待监控医疗单位的单方日均药品费用。
可选的，待监控医疗单位的单方日均药品费用(即待监控医疗单位在单个考核周期内的单方日均药品费用)可满足如下公式(3):
公式(3)：单方日均药品费用＝单方日均药品费用累加值/药品使用总天数累加值/单个考核周期的处方数量。
假设，这里单个考核周期为一个星期，则在上述公式(3)中的单方日均药品费用累加值可以是一个星期内的7个单日的中药处方中各个单日的中药处方的单方日均药品费用的累加值。上述公式(3)中的药品使用总天数累加值可以是一个星期内的7个单日的中药处方中各个单日的中药处方的药品使用总天数的累加值。
S23，根据上述待监控医疗单位的单位属性信息确定上述待监控医疗单位的单方日均药品费用阈值。
S24，根据上述待监控医疗单位的单方日均药品费用和上述确定的待监控医疗单位的单方日均药品费用阈值，确定待监控医疗单位的用药是否超标。
在一些可行的实施方式中，上述根据待监控医疗单位的单方日均药品费用，和待监控医疗单位对应的单方日均药品费用阈值确定待监控医疗单位的用药是否超标的具体实现方式可参见上述实施例中步骤S13所提供的实现方式，在此不再赘述。
可选的，在一些可行的实施方式中，针对不同医疗单位进行用药监控时，还可基于各个医疗单位的单位属性信息确定各个医疗单位的用药监控标准和/或用药评价标准的考核指标阈值，例如单方日均药品费用的不超标上限等。其中，上述待监控医疗单位的单位属性信息包括单位类型、单位所处地域、单位所处城市、单位药品供应渠道以及单位病患人次中的一种或多种，具体可根据实际应用场景确定，在此不做限制。例如，基于不同地域、不同城市、不同药品供应渠道或者不同病患流动量等参数所关联的不同医疗单元，用药监控的考核指标阈值可不尽相同。例如，对于物价较高的城市所关联的医疗单位或者药品供应渠道所带来的药品成本价较高所关联的医疗单元，则可将其单方日均药品费用的不超标上限可设置得较高一些，即其对应的用药监控标准的考核指标阈值则可设定为较高的考核指标等。对于物价较低的城市所关联的医疗单位或者药品供应渠道所带来的药品成本价较低所关联的医疗单元，则可将其单方日均药品费用的不超标上限可设置得较低一些，即其 对应的用药监控标准的考核指标阈值则可设定为较低的考核指标等。具体可根据实际应用场景确定，在此不做限制。
在一些可行的实施方式中，基于上述确定的待监控医疗单位的单方日均药品费用，结合基于待监控医疗单位的单位属性信息所确定的考核指标阈值(即单方日均药品费用上限)可确定该医疗单位的用药是否超标，换句话说，就是待监控医疗单位的单方日均药品费用是否小于或者等于其对应的单方日均药品费用上限。若待监控医疗单位的单方日均药品费用小于或者等于其对应的单方日均药品费用上限，则可确定待监控医疗单位的用药是不超标的，否则该医疗单位的用药则是超标的。
S25，若上述待监控医疗单位的中药饮片的用药超标，则基于上述单方日均药品费用对上述待监控医疗单位进行中药饮片药品费用超标的风险控制。
在一些可行的实施方式中，基于上述待监控医疗单位的单方日均药品费用对上述待监控医疗单位超标部分的单方日均药品费用差值进行公示，以实现对待监控医疗单位的中药处方的开方用药进行药品费用超标风险控制的实现方式可参见上述实施例中步骤S14所提供的实现方式，在此不再赘述。
可选的，在一些可行的实施方式中，基于上述单方日均药品费用差值，还可在接收到该待监控医疗单位提交的中药饮片的药品费用报销请求或者药品费用理赔请求时，可通过拒绝该待监控医疗单位的药品费用报销请求或者药品费用理赔请求，实现针对该待监控医疗单位的单方日均药品费用超标的这项考核标准进行惩罚，以对该医疗单位进行中药饮片的开方用药药品费用的风险控制。例如，当该医疗单位的某一天的单方日均药品费用超标时，可在接收到医疗单位提报的该天的药品费用报销和/或请求时，向该医疗单位反馈该天所有处方的药品费用的报销失败。换句话说，当该医疗单位的某一天的单方日均药品费用超标时，终端设备接收到医疗单位提报的该天的处方药品费用报销和/或理赔请求时，可对该医疗单位反馈该天的处方药品费用拒绝报销或者理赔，进而可提示该医疗单位对每天处方的单方日均药品费用进行自我把控以实现对该医疗单位的药品费用超标的处方风险控制。
可选的，在一些可行的实施方式中，当待监控医疗单位的用药标准超标，例如医疗单位单日处方的单方日均药品费用大于单方日均药品费用阈值时，终端设备可计算待监控医疗单位的单方日均药品费用与上述单方日均药品费用阈值之间的差值。当终端设备接收到该待监控医疗单位的药品费用报销和/或理赔请求时，则可针对该待监控医疗单位的单方日均药品费用与上述单方日均药品费用阈值之间的差值，对该待监控医疗单位单日处方的药品费用中差值部分药品费用拒绝报销或者理赔以对该医疗单位进行中药处方的药品费用超标的处方风险控制。
可选的，在一些可行的实施方式中，当终端设备确定待监控医疗单位某一个考核周期(例如一天或者一星期等)内的中药处方的用药超标，例如待监控医疗单位某个考核周期内的处方(例如单日处方)的单方日均药品费用大于单方日均药品费用阈值时，终端设备则可在该考核周期(单日处方的单方日均药品费用超标是某一天，例如周一)之后的下一个考核周期(单日处方的单方日均药品费用超标这天的第二天，例如周二)的开始时将该考核周期的单方日均药品费用超标报告传送给该待监控医疗单位。其中，该单方日均药品费用超标报告用于提示该待监控医疗单位在该考核周期内用药超标，并可提醒该待监控医 疗单位若在下一个考核周期或者指定时间内的连续多个考核周期内单方日均药品费用依然超标，则将对该待监控医疗单位进行单方日均药品费用超标的惩罚。其中，上述惩罚包括对该待监控医疗单位超标的单方日均药品费用全部拒绝报销或者理赔，或者对该待监控医疗单位的单方日均药品费用的超标部分拒绝报销或者理赔等。上述单方日均药品费用超标报告用于提示该待监控医疗单位对单方日均药品费用进行自我把控以实现对该待监控医疗单位的药品费用超标的风险控制。
基于本申请实施例提供的方法实现对各医疗单位的中药处方的用药监控操作方式多样，既可提高对医疗单位的中药饮片的用药监控的准确性，提高对医疗单位的用药监控的可靠性，同时也可增强对医疗单位的用药监控的操作灵活性。进而可提高用药超标的风险控制的可靠性，可提高该医疗单位开方的用药可控性，从而可提高医疗资源的有效利用率，适用性更强。
实施例三：
参见图3，图3是本申请实施例提供的基于数据处理的中药处方药品费用风险控制装置的实施例结构示意图。本申请实施例提供的基于数据处理的中药处方药品费用风险控制装置包括：
数据获取单元31，用于获取待监控医疗单位的中药处方，上述中药处方中包括至少一剂中药饮片。
药品信息处理单元32，用于获取上述数据获取单元31获取的上述中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定上述待监控医疗单位的单方日均药品费用。
用药评价单元33，用于根据上述药品信息处理单元32确定的上述单方日均药品费用，和上述待监控医疗单位对应的单方日均药品费用阈值确定上述待监控医疗单位的中药饮片的用药是否超标。
用药风险控制单元34，用于在上述用药评价单元33确定上述待监控医疗单位的中药饮片的用药超标时，基于上述药品信息处理单元32确定的上述单方日均药品费用对上述待监控医疗单位进行中药饮片药品费用超标的风险控制。
在一些可行的实施方式中，上述用药风险控制单元34用于：
将上述单方日均药品费用和/或上述单方日均药品费用超出上述单方日均药品费用阈值的差值进行公示，基于公示的上述单方日均药品费用和/或上述差值提示上述待监控医疗单位控制中药处方的中药饮片用药，以实现中药处方的药品费用超标风险控制；和/或
当接收到上述单方日均药品费用和/或上述差值对应的药品费用报销请求时，拒绝上述药品费用报销请求以实现中药处方的药品费用超标风险控制。
在一些可行的实施方式中，上述各剂中药饮片中一剂中药饮片中包括至少一种中药饮片，上述中药饮片药品信息至少包括药品费用和药品使用天数；上述药品信息处理单元32用于：
获取上述中药处方中各剂中药饮片所包括的各种中药饮片的药品费用，根据上述各种中药饮片的药品费用确定上述中药处方的药品总费用；
根据上述各剂中药饮片的药品使用天数确定上述中药处方的药品使用总天数，根据上 述药品总费用和上述药品使用总天数确定上述待监控医疗单位的单方日均药品费用。
其中，上述单方日均药品费用满足：
单方日均药品费用＝药品总费用/药品使用总天数。
在一些可行的实施方式中，上述药品信息处理单元32用于：
获取上述中药处方中任一剂中药饮片所包括的中药饮片的药品费用，根据上述任一剂中药饮片所包括的中药饮片的药品费用确定上述任一剂中药饮片的药品费用；
将上述中药处方中各剂中药饮片的药品费用的累计值确定为上述中药处方的药品总费用。
在一些可行的实施方式中，上述数据获取单元31用于：
获取上述待监控医疗单位的数据系统准入资格，基于上述数据系统准入资格从上述待监控医疗单位的数据系统中获取上述待监控医疗单位的中药处方；
其中，上述待监控医疗单位的中药处方包括上述待监控医疗单位的单个中药处方，或者上述待监控医疗单位在单个考核周期内的所有中药处方，上述单个考核周期的周期时长为一日或者大于一日。
在一些可行的实施方式中，上述数据获取单元31用于：
获取上述待监控医疗单位提供的医疗理赔数据，从上述医疗理赔数据中获取上述待监控医疗单位的中药处方；
其中，上述待监控医疗单位的中药处方包括上述待监控医疗单位的单个中药处方，或者上述待监控医疗单位在单个考核周期内的所有中药处方，上述单个考核周期的周期时长为一日或者大于一日。
在一些可行的实施方式中，上述待监控医疗单位的中药处方包括上述待监控医疗单位在单日时间内的所有中药处方；
上述药品信息处理单元32还用于：
获取上述所有中药处方中所包括的各种中药饮片的中药饮片药品信息，上述中药饮片药品信息中至少包括中药饮片的药品费用和药品使用天数；
根据上述各种中药饮片的药品费用确定上述所有中药处方所包括的所有中药饮片的药品总额，并根据上述各种中药饮片的药品使用天数确定上述所有中药处方的药品使用总天数；
根据上述药品总额和上述药品使用总天数确定上述待监控医疗单位的单方日均药品费用。
其中，上述待监控医疗单位的单方日均药品费用满足：
单方日均药品费用＝药品总额/药品使用总天数/处方数量。
在一些可行的实施方式中，上述待监控医疗单位的中药处方包括上述待监控医疗单位在多日的单个考核周期内的所有中药处方；
上述药品信息处理单元32还用于：
获取上述单个考核周期内任一日的中药处方，并获取上述任一日的中药处方中所包括的各种中药饮片的中药饮片药品信息，上述中药饮片药品信息中至少包括中药饮片的药品费用和药品使用天数；
根据上述任一日的中药处方所包括的各中药饮片的药品费用、药品使用天数和处方数量确定上述待监控医疗单位的单日的单方日均药品费用；
根据上述待监控医疗单位在上述单个考核周期内各日的单日的单方日均药品费用和药品使用总天数确定上述待监控医疗单位的单方日均药品费用；
其中，任一日的药品使用总天数为上述任一单日的中药处方中中药饮片的药品使用天数的总和。
在一些可行的实施方式中，上述药品信息处理单元32用于：
根据上述单个考核周期内各日的单日的单方日均药品费用确定上述单个考核周期的单日的单方日均药品费用累加值，根据上述单个考核周期内各日中药处方的中药饮片的药品使用总天数确定上述单个考核周期内的中药饮片的药品使用总天数累加值；
根据上述单日的单方日均药品费用累加值、上述药品使用总天数累加值和上述单个考核周期的处方数量确定上述待监控医疗单位的单方日均药品费用；
其中，上述待监控医疗单位的单方日均药品费用满足：
单方日均药品费用＝单日单方日均药品费用累加值/药品使用总天数累加值/单个考核周期的处方数量。
在一些可行的实施方式中，上述用药评价单元33还用于：
根据上述待监控医疗单位的单位属性信息确定上述待监控医疗单位的单方日均药品费用阈值；
其中，上述待监控医疗单位的单位属性信息包括单位类型、单位所处地域、单位所处城市、单位药品供应渠道以及单位病患人次中的一种或多种。
在一些可行的实施方式中，上述用药评价单元33用于：
在上述待监控医疗单位的单方日均药品费用小于或者等于上述单方日均药品费用阈值时，确定上述待监控医疗单位的用药不超标；
在上述待监控医疗单位的单方日均药品费用大于上述单方日均药品费用阈值时，确定上述待监控医疗单位的用药超标。
在一些可行的实施方式中，上述基于数据处理的中药处方药品费用风险控制装置可通过其内置的各个功能模块执行如上述图1至图2中各个步骤所提供的实现方式。可选的，上述基于数据处理的中药处方药品费用风险控制装置可为上述各个实施例中所描述的终端设备，在此不做限制。
在本申请实施例中，基于用药监控装置对各医疗单位的中药处方的用药监控操作方式多样，既可提高对医疗单位的中药饮片的用药监控的准确性，提高对医疗单位的用药监控的可靠性，同时也可增强对医疗单位的用药监控的操作灵活性。进而可提高用药超标的风险控制的可靠性，可提高该医疗单位开方的用药可控性，从而可提高医疗资源的有效利用率，适用性更强。
实施例四：
参见图4，图4是本申请实施例提供的一种终端设备的实施例结构示意图。如图4所示，本实施例中的终端设备可以包括：一个或多个处理器401和存储器402。上述处理器401和存储器402通过总线403连接。存储器402用于存储计算机程序，该计算机程序包 括程序指令，处理器401用于执行存储器402存储的程序指令。其中，上述处理器401被配置用于调用该程序指令执行如下操作：
获取待监控医疗单位的中药处方，上述中药处方中包括至少一剂中药饮片；
获取上述中药处方中各剂中药饮片的中药饮片药品信息，并根据上述中药饮片药品信息确定上述待监控医疗单位的单方日均药品费用；
根据上述单方日均药品费用和上述待监控医疗单位对应的单方日均药品费用阈值，确定上述待监控医疗单位的中药饮片的用药是否超标；
若上述待监控医疗单位的中药饮片的用药超标，则基于上述单方日均药品费用对上述待监控医疗单位进行中药饮片药品费用超标的风险控制。
在一些可行的实施方式中，上述处理器401用于：
将上述单方日均药品费用和/或上述单方日均药品费用超出上述单方日均药品费用阈值的差值进行公示，基于公示的上述单方日均药品费用和/或上述差值提示上述待监控医疗单位控制中药处方的中药饮片用药，以实现中药处方的药品费用超标风险控制；和/或
当接收到上述单方日均药品费用和/或上述差值对应的药品费用报销请求时，拒绝上述药品费用报销请求以实现中药处方的药品费用超标风险控制。
在一些可行的实施方式中，上述各剂中药饮片中一剂中药饮片中包括至少一种中药饮片，上述中药饮片药品信息至少包括药品费用和药品使用天数；上述处理器401，用于：
获取上述中药处方中各剂中药饮片所包括的各种中药饮片的药品费用，根据上述各种中药饮片的药品费用确定上述中药处方的药品总费用；
根据上述各剂中药饮片的药品使用天数确定上述中药处方的药品使用总天数，根据上述药品总费用和上述药品使用总天数确定上述待监控医疗单位的单方日均药品费用。
其中，上述单方日均药品费用满足：
单方日均药品费用＝药品总费用/药品使用总天数。
在一些可行的实施方式中，上述处理器401，用于：
获取上述中药处方中任一剂中药饮片所包括的中药饮片的药品费用，根据上述任一剂中药饮片所包括的中药饮片的药品费用确定上述任一剂中药饮片的药品费用；
将上述中药处方中各剂中药饮片的药品费用的累计值确定为上述中药处方的药品总费用。
在一些可行的实施方式中，上述处理器401，用于：
获取上述待监控医疗单位的数据系统准入资格，基于上述数据系统准入资格从上述待监控医疗单位的数据系统中获取上述待监控医疗单位的中药处方。
在一些可行的实施方式中，上述处理器401，用于：
获取上述待监控医疗单位提供的医疗理赔数据，从上述医疗理赔数据中获取上述待监控医疗单位的中药处方。
其中，上述待监控医疗单位的中药处方包括上述待监控医疗单位的单个中药处方，或者上述待监控医疗单位在单个考核周期内的所有中药处方，上述单个考核周期的周期时长包括一日或者大于一日。
在一些可行的实施方式中，上述待监控医疗单位的中药处方包括上述待监控医疗单位 在单日时间内的所有中药处方；
上述处理器401还用于：
获取上述所有中药处方中所包括的各种中药饮片的中药饮片药品信息，上述中药饮片药品信息中至少包括中药饮片的药品费用和药品使用天数；
根据上述各种中药饮片的药品费用确定上述所有中药处方所包括的所有中药饮片的药品总额，并根据上述各种中药饮片的药品使用天数确定上述所有中药处方的药品使用总天数；
根据上述药品总额、上述药品使用总天数和上述所有中药处方的处方数量确定上述待监控医疗单位的单方日均药品费用。
其中，上述待监控医疗单位的单方日均药品费用满足：
单方日均药品费用＝药品总额/药品使用总天数/处方数量。
在一些可行的实施方式中，上述待监控医疗单位的中药处方包括上述待监控医疗单位在多日的单个考核周期内的所有中药处方；
上述处理器401还用于：
获取上述单个考核周期内任一日的中药处方，并获取上述任一日的中药处方中所包括的各种中药饮片的中药饮片药品信息，上述中药饮片药品信息中至少包括中药饮片的药品费用和药品使用天数；
根据上述任一日的中药处方所包括的各中药饮片的药品费用、药品使用天数和处方数量确定上述待监控医疗单位的单日的单方日均药品费用；
根据上述待监控医疗单位在上述单个考核周期内各日的单日的单方日均药品费用、药品使用总天数和处方数量确定上述待监控医疗单位的单方日均药品费用；
其中，任一日的药品使用总天数为上述任一单日的中药处方中中药饮片的药品使用天数的总和。
在一些可行的实施方式中，上述处理器401用于：
根据上述单个考核周期内各日的单日的单方日均药品费用确定上述单个考核周期的单日的单方日均药品费用累加值，根据上述单个考核周期内各日中药处方的中药饮片的药品使用总天数确定上述单个考核周期内的中药饮片的药品使用总天数累加值；
根据上述单日的单方日均药品费用累加值、上述药品使用总天数累加值和上述单个考核周期的处方数量确定上述待监控医疗单位的单方日均药品费用；
其中，上述待监控医疗单位的单方日均药品费用满足：
单方日均药品费用＝单日单方日均药品费用累加值/药品使用总天数累加值/单个考核周期的处方数量。或者
可选的，上述待监控医疗单位的单方日均药品费用满足：
单方日均药品费用＝周期药品总费用/周期药品使用总天数/单个考核周期的处方数量；
其中，在上述周期药品总费用可以是单个考核周期内的所有中药处方中所包括的所有中药饮片的药品费用累加得到的所有中药饮片的药品总费用，上述周期药品使用总天数可以是单考核周期处方所包括的所有中药饮片中每个中药饮片的药品使用天数的累加值。
在一些可行的实施方式中，上述处理器401还用于：
根据上述待监控医疗单位的单位属性信息确定上述待监控医疗单位的单方日均药品费用阈值；
其中，上述待监控医疗单位的单位属性信息包括单位类型、单位所处地域、单位所处城市、单位药品供应渠道以及单位病患人次中的一种或多种。
在一些可行的实施方式中，上述处理器401用于：
在上述待监控医疗单位的单方日均药品费用小于或者等于上述单方日均药品费用阈值时，确定上述待监控医疗单位的用药不超标；
在上述待监控医疗单位的单方日均药品费用大于上述单方日均药品费用阈值时，确定上述待监控医疗单位的用药超标。
在一些可行的实施方式中，上述处理器401可以是中央处理单元(central processing unit，CPU)，该处理器还可以是其他通用处理器、数字信号处理器(digital signal processor，DSP)、专用集成电路(application specific integrated circuit，ASIC)、现成可编程门阵列(field-programmable gate array，FPGA)或者其他可编程逻辑器件、分立门或者晶体管逻辑器件、分立硬件组件等。通用处理器可以是微处理器或者该处理器也可以是任何常规的处理器等。
该存储器402可以包括只读存储器和随机存取存储器，并向处理器401提供指令和数据。存储器402的一部分还可以包括非易失性随机存取存储器。例如，存储器402还可以存储设备类型的信息。
在一些可行的实施方式中，上述终端设备可通过其内置的处理器401各个功能模块执行如上述图1至图2中各个步骤所提供的实现方式，具体可参见上述各个步骤所提供的实现方式，在此不再赘述。
基于终端设备对各医疗单位的中药处方的用药监控操作方式多样，既可提高对医疗单位的中药饮片的用药监控的准确性，提高对医疗单位的用药监控的可靠性，同时也可增强对医疗单位的用药监控的操作灵活性。进而可提高用药超标的风险控制的可靠性，可提高该医疗单位开方的用药可控性，从而可提高医疗资源的有效利用率，适用性更强。
本申请实施例还提供一种计算机可读存储介质，该计算机可读存储介质存储有计算机程序，该计算机程序包括程序指令，该程序指令被处理器执行时实现图1至图2中各个步骤所提供的基于数据处理的中药处方药品费用风险控制方法，具体可参见上述各个步骤所提供的实现方式，在此不再赘述。上述计算机可读存储介质可以是前述任一实施例提供的基于数据处理的中药处方药品费用风险控制装置或者上述终端设备的内部存储单元，例如电子设备的硬盘或内存。该计算机可读存储介质也可以是该电子设备的外部存储设备，例如该电子设备上配备的插接式硬盘，智能存储卡(smart media card,SMC)，安全数字(secure digital,SD)卡，闪存卡(flash card)等。
以上所述，仅为本申请的具体实施方式，但本申请的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本申请揭露的技术范围内，可轻易想到变化或替换，都应涵盖在本申请的保护范围之内。因此，本申请的保护范围应以所述权利要求的保护范围为准。

Claims (20)

  1. 一种基于数据处理的中药处方药品费用风险控制方法，其特征在于，所述方法包括：
    获取待监控医疗单位的中药处方，所述中药处方中包括至少一剂中药饮片；
    获取所述至少一剂中药饮片中各剂中药饮片的中药饮片药品信息，并根据所述中药饮片药品信息确定所述待监控医疗单位的单方日均药品费用；
    根据所述单方日均药品费用和所述待监控医疗单位对应的单方日均药品费用阈值，确定所述待监控医疗单位的中药饮片的用药是否超标；
    若所述待监控医疗单位的中药饮片的用药超标，则基于所述单方日均药品费用对所述待监控医疗单位进行中药饮片药品费用超标的风险控制。
  2. 根据权利要求1所述的方法，其特征在于，所述基于所述单方日均药品费用对所述待监控医疗单位进行中药饮片药品费用超标的风险控制包括：
    将所述单方日均药品费用和/或所述单方日均药品费用超出所述单方日均药品费用阈值的差值进行公示，基于公示的所述单方日均药品费用和/或所述差值提示所述待监控医疗单位控制中药处方的中药饮片用药，以实现中药处方的药品费用超标风险控制；和/或
    当接收到所述单方日均药品费用和/或所述差值对应的药品费用报销请求时，拒绝所述药品费用报销请求以实现中药处方的药品费用超标风险控制。
  3. 根据权利要求1或2所述的方法，其特征在于，所述各剂中药饮片中一剂中药饮片中包括至少一种中药饮片，所述中药饮片药品信息至少包括药品费用和药品使用天数；
    所述获取所述至少一剂中药饮片中各剂中药饮片的中药饮片药品信息，并根据所述中药饮片药品信息确定所述待监控医疗单位的单方日均药品费用包括：
    获取所述各剂中药饮片所包括的各种中药饮片的药品费用，根据所述各种中药饮片的药品费用确定所述中药处方的药品总费用；
    根据所述各剂中药饮片的药品使用天数确定所述中药处方的药品使用总天数，根据所述药品总费用和所述药品使用总天数确定所述待监控医疗单位的单方日均药品费用。
  4. 根据权利要求3所述的方法，其特征在于，所述获取所述各剂中药饮片所包括的各种中药饮片的药品费用，根据所述各种中药饮片的药品费用确定所述中药处方的药品总费用包括：
    获取所述中药处方中任一剂中药饮片所包括的中药饮片的药品费用，根据所述任一剂中药饮片所包括的中药饮片的药品费用确定所述任一剂中药饮片的药品费用；
    将所述至少一剂中药饮片中各剂中药饮片的药品费用的累计值确定为所述中药处方的药品总费用。
  5. 根据权利要求1-4任一项所述的方法，其特征在于，所述获取待监控医疗单位的中药处方包括：
    获取所述待监控医疗单位的数据系统准入资格，基于所述数据系统准入资格从所述待监控医疗单位的数据系统中获取所述待监控医疗单位的中药处方；和/或
    获取所述待监控医疗单位提供的医疗理赔数据，从所述医疗理赔数据中获取所述待监控医疗单位的中药处方。
  6. 根据权利要求5所述的方法，其特征在于，所述方法还包括：
    根据所述待监控医疗单位的单位属性信息确定所述待监控医疗单位的单方日均药品费用阈值；
    其中，所述待监控医疗单位的单位属性信息包括单位类型、单位所处地域、单位所处城市、单位药品供应渠道以及单位病患人次中的一种或多种。
  7. 根据权利要求6所述的方法，其特征在于，所述根据所述单方日均药品费用和所述待监控医疗单位对应的单方日均药品费用阈值，确定所述待监控医疗单位的中药饮片的用药是否超标包括：
    若所述待监控医疗单位的单方日均药品费用小于或者等于所述单方日均药品费用阈值，则确定所述待监控医疗单位的用药不超标；
    若所述待监控医疗单位的单方日均药品费用大于所述单方日均药品费用阈值，则确定所述待监控医疗单位的用药超标。
  8. 一种基于数据处理的中药处方药品费用风险控制装置，其特征在于，所述装置包括：
    数据获取单元，用于获取待监控医疗单位的中药处方，所述中药处方中包括至少一剂中药饮片；
    药品信息处理单元，用于获取所述数据获取单元获取的所述至少一剂中药饮片中各剂中药饮片的中药饮片药品信息，并根据所述中药饮片药品信息确定所述待监控医疗单位的单方日均药品费用；
    用药评价单元，用于根据所述药品信息处理单元确定的所述单方日均药品费用，和所述待监控医疗单位对应的单方日均药品费用阈值确定所述待监控医疗单位的中药饮片的用药是否超标；
    用药风险控制单元，用于在所述用药评价单元确定所述待监控医疗单位的中药饮片的用药超标时，基于所述药品信息处理单元确定的所述单方日均药品费用对所述待监控医疗单位进行中药饮片药品费用超标的风险控制。
  9. 根据权利要求8所述的装置，其特征在于，所述用药风险控制单元用于：
    将所述单方日均药品费用和/或所述单方日均药品费用超出所述单方日均药品费用阈值的差值进行公示，基于公示的所述单方日均药品费用和/或所述差值提示所述待监控医疗单位控制中药处方的中药饮片用药，以实现中药处方的药品费用超标风险控制；和/或
    当接收到所述单方日均药品费用和/或所述差值对应的药品费用报销请求时，拒绝所述药品费用报销请求以实现中药处方的药品费用超标风险控制。
  10. 根据权利要求8或9所述的装置，其特征在于，所述各剂中药饮片中一剂中药饮片中包括至少一种中药饮片，所述中药饮片药品信息至少包括药品费用和药品使用天数；所述药品信息处理单元用于：
    获取所述中药处方中各剂中药饮片所包括的各种中药饮片的药品费用，根据所述各种中药饮片的药品费用确定所述中药处方的药品总费用；
    根据所述各剂中药饮片的药品使用天数确定所述中药处方的药品使用总天数，根据所述药品总费用和所述药品使用总天数确定所述待监控医疗单位的单方日均药品费用。
  11. 根据权利要求10所述的装置，其特征在于，所述药品信息处理单元用于：
    获取所述中药处方中任一剂中药饮片所包括的中药饮片的药品费用，根据所述任一剂 中药饮片所包括的中药饮片的药品费用确定所述任一剂中药饮片的药品费用；
    将所述中药处方中各剂中药饮片的药品费用的累计值确定为所述中药处方的药品总费用。
  12. 根据权利要求8-11任一项所述的装置，其特征在于，所述数据获取单元用于：
    获取所述待监控医疗单位的数据系统准入资格，基于所述数据系统准入资格从所述待监控医疗单位的数据系统中获取所述待监控医疗单位的中药处方；和/或
    获取所述待监控医疗单位提供的医疗理赔数据，从所述医疗理赔数据中获取所述待监控医疗单位的中药处方；
    其中，所述待监控医疗单位的中药处方包括所述待监控医疗单位的单个中药处方，或者所述待监控医疗单位在单个考核周期内的所有中药处方，所述单个考核周期的周期时长包括一日或者大于一日。
  13. 根据权利要求12所述的装置，其特征在于，所述待监控医疗单位的中药处方包括所述待监控医疗单位单日的所有中药处方；
    所述药品信息处理单元用于：
    获取所述所有中药处方中所包括的各种中药饮片的中药饮片药品信息，所述中药饮片药品信息中至少包括中药饮片的药品费用和药品使用天数；
    根据所述各种中药饮片的药品费用确定所述所有中药处方所包括的所有中药饮片的药品总额，并根据所述各种中药饮片的药品使用天数确定所述所有中药处方的药品使用总天数；
    根据所述药品总额、所述药品使用总天数和所述所有中药处方的处方数量确定所述待监控医疗单位的单方日均药品费用。
  14. 根据权利要求12所述的装置，其特征在于，所述待监控医疗单位的中药处方包括所述待监控医疗单位在多日的单个考核周期内的所有中药处方；
    所述药品信息处理单元用于：
    获取所述单个考核周期内任一日的中药处方，并获取所述任一日的中药处方中所包括的各种中药饮片的中药饮片药品信息，所述中药饮片药品信息中至少包括中药饮片的药品费用和药品使用天数；
    根据所述任一日的中药处方所包括的各中药饮片的药品费用、药品使用天数和处方数量确定所述待监控医疗单位的单日的单方日均药品费用；
    根据所述待监控医疗单位在所述单个考核周期内各日的单日的单方日均药品费用、药品使用总天数和单个考核周期的处方数量确定所述待监控医疗单位的单方日均药品费用；
    其中，任一日的药品使用总天数为所述任一单日的中药处方中中药饮片的药品使用天数的总和。
  15. 根据权利要求12所述的装置，其特征在于，所述用药评价单元还用于：
    根据所述待监控医疗单位的单位属性信息确定所述待监控医疗单位的单方日均药品费用阈值；
    其中，所述待监控医疗单位的单位属性信息包括单位类型、单位所处地域、单位所处城市、单位药品供应渠道以及单位病患人次中的一种或多种。
  16. 根据权利要求15所述的装置，其特征在于，所述用药评价单元用于：
    在所述待监控医疗单位的单方日均药品费用小于或者等于所述单方日均药品费用阈值时，确定所述待监控医疗单位的用药不超标；
    在所述待监控医疗单位的单方日均药品费用大于所述单方日均药品费用阈值时，确定所述待监控医疗单位的用药超标。
  17. 一种终端设备，其特征在于，包括处理器和存储器，所述处理器和存储器相互连接，其中，所述存储器用于存储计算机程序，所述计算机程序包括程序指令，所述处理器被配置用于调用所述程序指令执行如下操作：
    获取待监控医疗单位的中药处方，所述中药处方中包括至少一剂中药饮片；
    获取所述至少一剂中药饮片中各剂中药饮片的中药饮片药品信息，并根据所述中药饮片药品信息确定所述待监控医疗单位的单方日均药品费用；
    根据所述单方日均药品费用和所述待监控医疗单位对应的单方日均药品费用阈值，确定所述待监控医疗单位的中药饮片的用药是否超标；
    若所述待监控医疗单位的中药饮片的用药超标，则基于所述单方日均药品费用对所述待监控医疗单位进行中药饮片药品费用超标的风险控制。
  18. 根据权利要求17所述的终端设备，其特征在于，所述处理器用于：
    将所述单方日均药品费用和/或所述单方日均药品费用超出所述单方日均药品费用阈值的差值进行公示，基于公示的所述单方日均药品费用和/或所述差值提示所述待监控医疗单位控制中药处方的中药饮片用药，以实现中药处方的药品费用超标风险控制；和/或
    当接收到所述单方日均药品费用和/或所述差值对应的药品费用报销请求时，拒绝所述药品费用报销请求以实现中药处方的药品费用超标风险控制。
  19. 根据权利要求17或18所述的终端设备，其特征在于，所述各剂中药饮片中一剂中药饮片中包括至少一种中药饮片，所述中药饮片药品信息至少包括药品费用和药品使用天数；
    所述处理器用于：
    获取所述各剂中药饮片所包括的各种中药饮片的药品费用，根据所述各种中药饮片的药品费用确定所述中药处方的药品总费用；
    根据所述各剂中药饮片的药品使用天数确定所述中药处方的药品使用总天数，根据所述药品总费用和所述药品使用总天数确定所述待监控医疗单位的单方日均药品费用。
  20. 一种计算机可读存储介质，其特征在于，所述计算机可读存储介质存储有计算机程序，所述计算机程序被处理器执行以实现权利要求1-7任一项所述的方法。
PCT/CN2019/094998 2018-10-22 2019-07-08 基于数据处理的中药处方药品费用风险控制方法及装置 WO2020082787A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811232863.6A CN109360622A (zh) 2018-10-22 2018-10-22 基于数据处理的中药处方药品费用风险控制方法及装置
CN201811232863.6 2018-10-22

Publications (1)

Publication Number Publication Date
WO2020082787A1 true WO2020082787A1 (zh) 2020-04-30

Family

ID=65346126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/094998 WO2020082787A1 (zh) 2018-10-22 2019-07-08 基于数据处理的中药处方药品费用风险控制方法及装置

Country Status (2)

Country Link
CN (1) CN109360622A (zh)
WO (1) WO2020082787A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109360622A (zh) * 2018-10-22 2019-02-19 平安医疗健康管理股份有限公司 基于数据处理的中药处方药品费用风险控制方法及装置
CN109524077A (zh) * 2018-10-22 2019-03-26 平安医疗健康管理股份有限公司 基于数据处理的中药处方药品费用控制方法及装置
CN109523762A (zh) * 2018-10-22 2019-03-26 平安医疗健康管理股份有限公司 基于数据处理的中药处方药品费用超标预警方法及装置
CN109360623A (zh) * 2018-10-22 2019-02-19 平安医疗健康管理股份有限公司 基于数据处理的用药处方风险控制方法及装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103985075A (zh) * 2014-05-30 2014-08-13 厦门市智业软件工程有限公司 一种医院成本的分摊方法
CN108172302A (zh) * 2017-12-15 2018-06-15 广州市康软信息科技有限公司 合理用药信息监测方法及系统
CN109360622A (zh) * 2018-10-22 2019-02-19 平安医疗健康管理股份有限公司 基于数据处理的中药处方药品费用风险控制方法及装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7558380B2 (en) * 2003-09-25 2009-07-07 Ateb, Inc. Methods, systems and computer program products for providing targeted messages for pharmacy interactive voice response (IVR) systems
CN103514576A (zh) * 2013-09-06 2014-01-15 深圳民太安信息技术有限公司 一种社保就诊违规套现的筛查方法
CN106530166B (zh) * 2016-08-31 2019-12-13 中国人民解放军总医院第一附属医院 医院医保费用防拒付辅助管理信息系统及防拒付方法
CN107123072A (zh) * 2017-05-11 2017-09-01 杭州逸曜信息技术有限公司 医疗费用限制规则生成方法
CN107609980A (zh) * 2017-09-07 2018-01-19 平安医疗健康管理股份有限公司 医疗数据处理方法、装置、计算机设备及存储介质
CN108460693A (zh) * 2018-03-29 2018-08-28 平安健康保险股份有限公司 保险合作医院的品质监控方法及装置、存储介质及终端

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103985075A (zh) * 2014-05-30 2014-08-13 厦门市智业软件工程有限公司 一种医院成本的分摊方法
CN108172302A (zh) * 2017-12-15 2018-06-15 广州市康软信息科技有限公司 合理用药信息监测方法及系统
CN109360622A (zh) * 2018-10-22 2019-02-19 平安医疗健康管理股份有限公司 基于数据处理的中药处方药品费用风险控制方法及装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
程苏华 (CHENG, SUHUA): "智能审核系统在门诊费用管理中的应用 (Application of Intelligent Audit System in Outpatient Expenses Management),", 医院管理论坛 (HOSPITAL MANAGEMENT FORUM), vol. 33, no. 3, 31 March 2016 (2016-03-31) *

Also Published As

Publication number Publication date
CN109360622A (zh) 2019-02-19

Similar Documents

Publication Publication Date Title
WO2020082787A1 (zh) 基于数据处理的中药处方药品费用风险控制方法及装置
WO2020082794A1 (zh) 基于数据处理的中药处方药品费用超标预警方法及装置
WO2020082805A1 (zh) 基于数据处理的中药处方药品费用控制方法及装置
Tidwell et al. Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-Ar protocol
WO2020082798A1 (zh) 基于数据处理的中药处方药品费用控制方法及装置
Chow et al. Literature Review of Traditional Chinese Medicine Herbs–Induced Liver Injury From an Oncological Perspective With RUCAM
WO2020082790A1 (zh) 基于数据处理的中药处方用药监控方法及装置
Liu et al. The Effects of Modified Simiao Decoction in the Treatment of Gouty Arthritis: A Systematic Review and Meta‐Analysis
Blais et al. Accuracy of the days’ supply and the number of refills allowed recorded in Québec prescription claims databases for inhaled corticosteroids
WO2020082789A1 (zh) 基于数据处理的中药处方药品费用超标预警方法及装置
Lee et al. Traditional east asian herbal medicine treatment for Alzheimer’s Disease: a systematic review and meta-analysis
WO2020082784A1 (zh) 基于数据处理的中药处方用药监控方法及装置
Zhong et al. Chinese Herbal Medicine (Zi Shen Qing) for Mild‐to‐Moderate Systematic Lupus Erythematosus: A Pilot Prospective, Single‐Blinded, Randomized Controlled Study
Jansson et al. Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
Zhou et al. Efficacy and safety of suanzaoren decoction for chronic insomnia disorder in adults: study protocol for randomised, double-blind, double-dummy, placebo-controlled trial
WO2020082785A1 (zh) 基于数据处理的用药处方风险控制方法及装置
Xiong et al. Market access for Chinese herbal medicinal products in Europe—A ten-year review of relevant products, policies, and challenges
Weng et al. Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for patients with myasthenia gravis: Study protocol for a series of randomized, controlled N-of-1 trials
Cheon et al. Single-arm, open-label, dose-escalation phase I study to evaluate the safety of a herbal medicine SH003 in patients with solid cancer: a study protocol
CN109545308A (zh) 基于数据处理的中药处方药品费用超标预警方法及装置
Nascimento et al. Potential drug therapy problems on an elderly nursing home population
Liao et al. Concurrent use of corticosteroids with licorice-containing TCM preparations in Taiwan: A National Health Insurance Database study
Liu et al. Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial
Houle et al. Should vitamin B12 tablets be included in more Canadian drug formularies? an economic model of the cost-saving potential from increased utilisation of oral versus intramuscular vitamin B12 maintenance therapy for Alberta seniors
CN110299197A (zh) 一种中药处方代煎自动审核系统

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19876856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19876856

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 19876856

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 22/12/2021)